Current advances in nanoformulations of therapeutic agents targeting tumor microenvironment to overcome drug resistance

1.

Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., et al. (2018). Understanding the tumor immune microenvironment (TIME) for effective therapy. Nature Medicine, 24(5), 541–550. https://doi.org/10.1038/s41591-018-0014-xCrossRefPubMedPubMedCentral

2.

Pearce, O. M., Delaine-Smith, R. M., Maniati, E., Nichols, S., Wang, J., Böhm, S., et al. (2018). Deconstruction of a metastatic tumor microenvironment reveals a common matrix response in human cancers. Cancer Discovery, 8(3), 304–319. https://doi.org/10.1158/2159-8290

3.

Liu, J., Chen, Q., Feng, L., & Liu, Z. (2018). Nanomedicine for tumor microenvironment modulation and cancer treatment enhancement. Nano Today, 21, 55–73. https://doi.org/10.1016/j.nantod.2018.06.008CrossRef

4.

Kondo, A., Yamamoto, S., Nakaki, R., Shimamura, T., Hamakubo, T., Sakai, J., et al. (2017). Extracellular acidic pH activates the sterol regulatory element-binding protein 2 to promote tumor progression. Cell Reports, 18(9), 2228–2242. https://doi.org/10.1016/j.celrep.2017.02.006CrossRefPubMed

5.

Vaupel, P., & Mayer, A. (2007). Hypoxia in cancer: Significance and impact on clinical outcome. Cancer and Metastasis Reviews, 26(2), 225–239. https://doi.org/10.1007/s10555-007-9055-1

6.

Wang, Y., Shang, W., Niu, M., Tian, J., & Xu, K. (2019). Hypoxia-active nanoparticles used in tumor theranostic. International Journal of Nanomedicine, 14, 3705. https://doi.org/10.2147/IJN.S196959

7.

Kumari, R., Sunil, D., & Ningthoujam, R. S. (2020). Hypoxia-responsive nanoparticle based drug delivery systems in cancer therapy: An up-to-date review. Journal of Controlled Release, 319, 135–156. https://doi.org/10.1016/j.jconrel.2019.12.041

8.

Bae, Y. M., Park, Y. I., Nam, S. H., Kim, J. H., Lee, K., Kim, H. M., et al. (2012). Endocytosis, intracellular transport, and exocytosis of lanthanide-doped upconverting nanoparticles in single living cells. Biomaterials, 33(35), 9080–9086. https://doi.org/10.1016/j.biomaterials.2012.08.039

9.

Kwon, E. J., Lo, J. H., & Bhatia, S. N. (2015). Smart nanosystems: Bio-inspired technologies that interact with the host environment. Proceedings of the National Academy of Sciences, 112(47), 14460–14466. https://doi.org/10.1073/pnas.1508522112

10.

Lee, P., Chandel, N. S., & Simon, M. C. (2020). Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. Nature Reviews Molecular Cell Biology, 21(5), 268–283. https://doi.org/10.1038/s41580-020-0227-yCrossRefPubMedPubMedCentral

11.

Swinson, D. E., Jones, J. L., Richardson, D., Wykoff, C., Turley, H., Pastorek, J., et al. (2003). Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. Journal of Clinical Oncology, 21(3), 473–482. https://doi.org/10.1200/JCO.2003.11.132CrossRefPubMed

12.

Balkwill, F. R., Capasso, M., & Hagemann, T. (2012). The tumor microenvironment at a glance. Journal of Cell Science, 125(23), 5591–5596. https://doi.org/10.1242/jcs.116392CrossRefPubMed

13.

Colby, A. H., Oberlies, N. H., Pearce, C. J., Herrera, V. L., Colson, Y. L., & Grinstaff, M. W. (2017). Nanoparticle drug-delivery systems for peritoneal cancers: A case study of the design, characterization and development of the expansile nanoparticle. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 9(3), e1451. https://doi.org/10.1002/wnan.1451

14.

Ruan, S., Cao, X., Cun, X., Hu, G., Zhou, Y., Zhang, Y., et al. (2015). Matrix metalloproteinase-sensitive size-shrinkable nanoparticles for deep tumor penetration and pH triggered doxorubicin release. Biomaterials, 60, 100–110. https://doi.org/10.1016/j.biomaterials.2015.05.006CrossRefPubMed

15.

Hu, C., Cun, X., Ruan, S., Liu, R., Xiao, W., Yang, X., et al. (2018). Enzyme-triggered size shrink and laser-enhanced NO release nanoparticles for deep tumor penetration and combination therapy. Biomaterials, 168, 64–75. https://doi.org/10.1016/j.biomaterials.2018.03.046CrossRefPubMed

16.

Meng, H., Xing, G., Blanco, E., Song, Y., Zhao, L., Sun, B., et al. (2012). Gadolinium metallofullerenol nanoparticles inhibit cancer metastasis through matrix metalloproteinase inhibition: Imprisoning instead of poisoning cancer cells. Nanomedicine: Nanotechnology, Biology and Medicine, 8(2), 136–146. https://doi.org/10.1016/j.nano.2011.08.019CrossRefPubMed

17.

Cathcart, J., Pulkoski-Gross, A., & Cao, J. (2015). Targeting matrix metalloproteinases in cancer: Bringing new life to old ideas. Genes & Diseases, 2(1), 26–34. https://doi.org/10.1016/j.gendis.2014.12.002

18.

Zhang, B., Zhang, Y., Liao, Z., Jiang, T., Zhao, J., Tuo, Y., et al. (2015). UPA-sensitive ACPP-conjugated nanoparticles for multi-targeting therapy of brain glioma. Biomaterials, 36, 98–109. https://doi.org/10.1016/j.biomaterials.2014.09.008CrossRefPubMed

19.

Zhang, B., Jiang, T., Ling, L., Cao, Z., Zhao, J., Tuo, Y., et al. (2016). Enhanced antitumor activity of EGFP-EGF1-conjugated nanoparticles by a multitargeting strategy. ACS Applied Materials & Interfaces, 8(14), 8918–8927. https://doi.org/10.1021/acsami.6b00036CrossRef

20.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013CrossRefPubMed

21.

Egeblad, M., Rasch, M. G., & Weaver, V. M. (2010). Dynamic interplay between the collagen scaffold and tumor evolution. Current Opinion in Cell Biology, 22(5), 697–706. https://doi.org/10.1016/j.ceb.2010.08.015CrossRefPubMedPubMedCentral

22.

Lu, P., Weaver, V. M., & Werb, Z. (2012). The extracellular matrix: A dynamic niche in cancer progression. Journal of Cell Biology, 196(4), 395–406. https://doi.org/10.1083/jcb.201102147CrossRefPubMedPubMedCentral

23.

Brennen, W. N., Rosen, D. M., Wang, H., Isaacs, J. T., & Denmeade, S. R. (2012). Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. Journal of the National Cancer Institute, 104(17), 1320–1334. https://doi.org/10.1093/jnci/djs336CrossRefPubMedPubMedCentral

24.

Miao, L., Newby, J. M., Lin, C. M., Zhang, L., Xu, F., Kim, W. Y., et al. (2016). The binding site barrier elicited by tumor-associated fibroblasts interferes disposition of nanoparticles in stroma-vessel type tumors. ACS Nano, 10(10), 9243–9258. https://doi.org/10.1021/acsnano.6b02776CrossRefPubMedPubMedCentral

25.

Engblom, C., Pfirschke, C., & Pittet, M. J. (2016). The role of myeloid cells in cancer therapies. Nature Reviews Cancer, 16(7), 447–462. https://doi.org/10.1038/nrc.2016.54CrossRefPubMed

26.

Gun, S. Y., Lee, S. W. L., Sieow, J. L., & Wong, S. C. (2019). Targeting immune cells for cancer therapy. Redox Biology, 25, 101174. https://doi.org/10.1016/j.redox.2019.101174CrossRefPubMedPubMedCentral

27.

Hinshaw, D. C., & Shevde, L. A. (2019). The tumor microenvironment innately modulates cancer progression. Cancer Research, 79(18), 4557–4566. https://doi.org/10.1158/0008-5472.CAN-18-3962CrossRefPubMedPubMedCentral

28.

Chang, C.-H., Curtis, J. D., Maggi, L. B., Jr., Faubert, B., Villarino, A. V., O’Sullivan, D., et al. (2013). Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell, 153(6), 1239–1251. https://doi.org/10.1016/j.cell.2013.05.016CrossRefPubMedPubMedCentral

29.

Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., et al. (2015). Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell, 162(6), 1229–1241. https://doi.org/10.1016/j.cell.2015.08.016CrossRefPubMedPubMedCentral

30.

Mescher, M. F., Curtsinger, J. M., Agarwal, P., Casey, K. A., Gerner, M., Hammerbeck, C. D., et al. (2006). Signals required for programming effector and memory development by CD8+ T cells. Immunological Reviews, 211(1), 81–92. https://doi.org/10.1111/j.0105-2896.2006.00382.xCrossRefPubMed

31.

Crespo, J., Sun, H., Welling, T. H., Tian, Z., & Zou, W. (2013). T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Current Opinion in Immunology, 25(2), 214–221. https://doi.org/10.1016/j.coi.2012.12.003CrossRefPubMedPubMedCentral

32.

Das, M., Zhu, C., & Kuchroo, V. K. (2017). Tim-3 and its role in regulating anti-tumor immunity. Immunological Reviews, 276(1), 97–111. https://doi.org/10.1111/imr.12520CrossRefPubMedPubMedCentral

33.

Cong, J., Wang, X., Zheng, X., Wang, D., Fu, B., Sun, R., et al. (2018). Dysfunction of natural killer cells by FBP1-induced inhibition of glycolysis during lung cancer progression. Cell Metabolism, 28(2), 243–255. e245. https://doi.org/10.1016/j.cmet.2018.06.021CrossRefPubMed

34.

Mah, A. Y., & Cooper, M. A. (2016). Metabolic regulation of natural killer cell IFN-γ production. Critical Reviews in Immunology, 36(2), 131. https://doi.org/10.1615/CritRevImmunol.2016017387

35.

Young, A., Ngiow, S. F., Gao, Y., Patch, A.-M., Barkauskas, D. S., Messaoudene, M., et al. (2018). A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment. Cancer Research, 78(4), 1003–1016. https://doi.org/10.1158/0008-5472.CAN-17-2826CrossRefPubMed

36.

Brand, A., Singer, K., Koehl, G. E., Kolitzus, M., Schoenhammer, G., Thiel, A., et al. (2016). LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metabolism, 24(5), 657–671. https://doi.org/10.1016/j.cmet.2016.08.011CrossRefPubMed

37.

Aster, J. C., Pear, W. S., & Blacklow, S. C. (2017). The varied roles of Notch in cancer. Annual Review of Pathology: Mechanisms of Disease, 12, 245–275. https://doi.org/10.1146/annurev-pathol-052016-100127CrossRef

38.

Nowell, C. S., & Radtke, F. (2017). Notch as a tumour suppressor. Nature Reviews Cancer, 17(3), 145–159. https://doi.org/10.1038/nrc.2016.145CrossRefPubMed

39.

Ntziachristos, P., Lim, J. S., Sage, J., & Aifantis, I. (2014). From fly wings to targeted cancer therapies: A centennial for notch signaling. Cancer Cell, 25(3), 318–334. https://doi.org/10.1038/nrc.2016.145CrossRefPubMedPubMedCentral

40.

Newman, D. J., & Cragg, G. M. (2020). Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. Journal of Natural Products, 83(3), 770–803. https://doi.org/10.1021/acs.jnatprod.9b01285CrossRefPubMed

41.

Cragg, G. M., & Pezzuto, J. M. (2016). Natural products as a vital source for the discovery of cancer chemotherapeutic and chemopreventive agents. Medical Principles and Practice, 25(Suppl. 2), 41–59. https://doi.org/10.1159/000443404CrossRefPubMed

42.

Atanasov, A. G., Zotchev, S. B., Dirsch, V. M., & Supuran, C. T. (2021). Natural products in drug discovery: Advances and opportunities. Nature Reviews. Drug Discovery, 20(3), 200–216. https://doi.org/10.1038/s41573-020-00114-zCrossRefPubMedPubMedCentral

43.

Bishayee, A., & Sethi, G. (2016). Bioactive natural products in cancer prevention and therapy: Progress and promise. Seminars in Cancer Biology, 40, 1–3. https://doi.org/10.1016/j.semcancer.2016.08.006

44.

G, M. S., Swetha, M., Keerthana, C. K., Rayginia, T. P., & Anto, R. J. (2021). Cancer chemoprevention: A strategic approach using phytochemicals. Frontiers in Pharmacology, 12, 809308. https://doi.org/10.3389/fphar.2021.809308

45.

Choudhari, A. S., Mandave, P. C., Deshpande, M., Ranjekar, P., & Prakash, O. (2019). Phytochemicals in cancer treatment: From preclinical studies to clinical practice. Frontiers in Pharmacology, 10, 1614. https://doi.org/10.3389/fphar.2019.01614CrossRefPubMed

46.

Sacks, D., Baxter, B., Campbell, B. C. V., Carpenter, J. S., Cognard, C., Dippel, D., et al. (2018). Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke. International Journal of Stroke, 13(6), 612–632. https://doi.org/10.1177/1747493018778713CrossRefPubMed

47.

Islam, M. T. (2017). Diterpenes and their derivatives as potential anticancer agents. Phytotherapy Research, 31(5), 691–712. https://doi.org/10.1002/ptr.5800CrossRefPubMed

48.

Pascolutti, M., & Quinn, R. J. (2014). Natural products as lead structures: Chemical transformations to create lead-like libraries. Drug Discovery Today, 19(3), 215–221. https://doi.org/10.1016/j.drudis.2013.10.013CrossRefPubMed

49.

Ghanbari-Movahed, M., Jackson, G., Farzaei, M. H., & Bishayee, A. (2021). A systematic review of the preventive and therapeutic effects of naringin against human malignancies. Frontiers in Pharmacology, 12, 250. https://doi.org/10.3389/fphar.2021.639840CrossRef

50.

Sak, K. (2014). Cytotoxicity of dietary flavonoids on different human cancer types. Pharmacognosy Reviews, 8(16), 122. https://doi.org/10.4103/0973-7847.134247CrossRefPubMedPubMedCentral

51.

Tewari, D., Priya, A., Bishayee, A., & Bishayee, A. (2022). Targeting transforming growth factor-β signalling for cancer prevention and intervention: Recent advances in developing small molecules of natural origin. Clinical and Translational Medicine, 12(4), e795. https://doi.org/10.1002/ctm2.795CrossRefPubMedPubMedCentral

52.

Fakhri, S., Moradi, S. Z., Yarmohammadi, A., Narimani, F., Wallace, C. E., & Bishayee, A. (2022). Modulation of TLR/NF-κB/NLRP signaling by bioactive phytocompounds: A promising strategy to augment cancer chemotherapy and immunotherapy. Frontiers in Pharmacology, 12, 834072. https://doi.org/10.3389/fonc.2022.834072CrossRef

53.

Fakhri, S., Moradi, S. Z., Ash-Rafzadeh, A., & Bishayee, A. (2022). Targeting cellular senescence in cancer by plant secondary metabolites: A systematic review. Pharmacological Research, 177, 105961. https://doi.org/10.1016/j.phrs.2021.105961CrossRefPubMed

54.

Bose, S., Banerjee, S., Mondal, A., Chakraborty, U., Pumarol, J., Croley, C. R., et al. (2020). Targeting the JAK/STAT signaling pathway using phytocompounds for cancer prevention and therapy. Cells, 9(6), 1451. https://doi.org/10.3390/cells9061451CrossRefPubMedPubMedCentral

55.

Braicu, C., Zanoaga, O., Zimta, A. A., Tigu, A. B., Kilpatrick, K. L., Bishayee, A., et al. (2022). Natural compounds modulate the crosstalk between apoptosis- and autophagy-regulated signaling pathways: Controlling the uncontrolled expansion of tumor cells. Seminars in Cancer Biology, 80, 218–236. https://doi.org/10.1016/j.semcancer.2020.05.015CrossRefPubMed

56.

Fakhri, S., Moradi, S. Z., Farzaei, M. H., & Bishayee, A. (2022). Modulation of dysregulated cancer metabolism by plant secondary metabolites: A mechanistic review. Seminars in Cancer Biology, 80, 276–305. https://doi.org/10.1016/j.semcancer.2020.02.007CrossRefPubMed

57.

Tewari, D., Patni, P., Bishayee, A., Sah, A. N., & Bishayee, A. (2022). Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy. Seminars in Cancer Biology, 80, 1–17. https://doi.org/10.1016/j.semcancer.2019.12.008CrossRefPubMed

58.

Lagoa, R., Silva, J., Rodrigues, J. R., & Bishayee, A. (2020). Advances in phytochemical delivery systems for improved anticancer activity. Biotechnology Advances, 38, 107382. https://doi.org/10.1016/j.biotechadv.2019.04.004CrossRefPubMed

59.

Kashyap, D., Tuli, H. S., Yerer, M. B., Sharma, A., Sak, K., Srivastava, S., et al. (2021). Natural product-based nanoformulations for cancer therapy: Opportunities and challenges. Seminars in Cancer Biology, 69, 5–23. https://doi.org/10.1016/j.semcancer.2019.08.014CrossRefPubMed

60.

Allen, T. M., & Cullis, P. R. (2004). Drug delivery systems: Entering the mainstream. Science, 303(5665), 1818–1822. https://doi.org/10.1126/science.1095833CrossRefPubMed

61.

Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007). Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2(12), 751–760. https://doi.org/10.1038/nnano.2007.387CrossRefPubMed

62.

Prabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W., Farokhzad, O. C., et al. (2013). Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. AACR. Cancer Research, 73, 2412. https://doi.org/10.1158/0008-5472.CAN-12-4561CrossRefPubMedPubMedCentral

63.

Greish, K., Frandsen, J., Scharff, S., Gustafson, J., Cappello, J., Li, D., et al. (2010). Silk-elastinlike protein polymers improve the efficacy of adenovirus thymidine kinase enzyme prodrug therapy of head and neck tumors. The Journal of Gene Medicine, 12(7), 572–579. https://doi.org/10.1002/jgm.1469CrossRefPubMedPubMedCentral

64.

Maeda, H. (2010). Tumor-selective delivery of macromolecular drugs via the EPR effect: Background and future prospects. Bioconjugate Chemistry, 21(5), 797–802. https://doi.org/10.1021/bc100070gCrossRefPubMed

65.

Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017). Cancer nanomedicine: Progress, challenges and opportunities. Nature Reviews Cancer, 17(1), 20–37. https://doi.org/10.1038/nrc.2016.108CrossRefPubMed

66.

von Roemeling, C., Jiang, W., Chan, C. K., Weissman, I. L., & Kim, B. Y. (2017). Breaking down the barriers to precision cancer nanomedicine. Trends in Biotechnology, 35(2), 159–171. https://doi.org/10.1016/j.tibtech.2016.07.006CrossRef

67.

Kashyap, D., Tuli, H. S., Yerer, M. B., Sharma, A., Sak, K., Srivastava, S., et al. (2021). Natural product-based nanoformulations for cancer therapy: Opportunities and challenges. Seminars in Cancer Biology, 69, 5–23. https://doi.org/10.1016/j.semcancer.2019.08.014

68.

Su, Z., Dong, S., Zhao, S.-C., Liu, K., Tan, Y., Jiang, X., et al. (2021). Novel nanomedicines to overcome cancer multidrug resistance. Drug Resistance Updates, 58, 100777. https://doi.org/10.1016/j.drup.2021.100777CrossRefPubMed

69.

Huang, Y., Wang, T., Yang, J., Wu, X., Fan, W., & Chen, J. (2022). Current strategies for the treatment of hepatocellular carcinoma by modulating the tumor microenvironment via nano-delivery systems: A review. International Journal of Nanomedicine, 17, 2335–2352. https://doi.org/10.2147/ijn.s363456CrossRefPubMedPubMedCentral

70.

Gu, X., Gao, Y., Wang, P., Wang, L., Peng, H., He, Y., et al. (2021). Nano-delivery systems focused on tumor microenvironment regulation and biomimetic strategies for treatment of breast cancer metastasis. Journal of Controlled Release, 333, 374–390. https://doi.org/10.1016/j.jconrel.2021.03.039CrossRefPubMed

71.

Girish, B. P., Dariya, B., Mannarapu, M., Nagaraju, G. P., & Raju, G. S. R. (2022). Targeting the tumor microenvironment of pancreatic ductal adenocarcinoma using nano-phytomedicines. Seminars in Cancer Biology, 86(Pt 2), 1155–1162. https://doi.org/10.1016/j.semcancer.2021.06.014CrossRefPubMed

72.

Jain, R. K. (2014). Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia. Cancer Cell, 26(5), 605–622. https://doi.org/10.1016/j.ccell.2014.10.006CrossRefPubMedPubMedCentral

73.

Martin, J. D., Seano, G., & Jain, R. K. (2019). Normalizing function of tumor vessels: Progress, opportunities, and challenges. Annual Review of Physiology, 81, 505–534. https://doi.org/10.1146/annurev-physiol-020518-114700CrossRefPubMedPubMedCentral

74.

Viallard, C., & Larrivée, B. (2017). Tumor angiogenesis and vascular normalization: Alternative therapeutic targets. Angiogenesis, 20(4), 409–426. https://doi.org/10.1007/s10456-017-9562-9CrossRefPubMed

75.

Fan, C., Zhang, S., Gong, Z., Li, X., Xiang, B., Deng, H., et al. (2021). Emerging role of metabolic reprogramming in tumor immune evasion and immunotherapy. Science China Life Sciences, 64(4), 534–547. https://doi.org/10.1007/s11427-019-1735-4CrossRefPubMed

76.

Hanahan, D., & Coussens, L. M. (2012). Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell, 21(3), 309–322. https://doi.org/10.1016/j.ccr.2012.02.022CrossRefPubMed

77.

Azab, A. K., Hu, J., Quang, P., Azab, F., Pitsillides, C., Awwad, R., et al. (2012). Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood, The Journal of the American Society of Hematology, 119(24), 5782–5794. https://doi.org/10.1182/blood-2011-09-380410CrossRef

78.

Zhao, X., Gao, S., Ren, H., Sun, W., Zhang, H., Sun, J., et al. (2014). Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actin-bundling protein fascin. Cancer Research, 74(9), 2455–2464. https://doi.org/10.1158/0008-5472.CAN-13-3009CrossRefPubMed

79.

Folkman, J. (2006). Angiogenesis. Annual Review of Medicine, 57, 1–18. https://doi.org/10.1146/annurev.med.57.121304.131306CrossRefPubMed

80.

Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003). The biology of VEGF and its receptors. Nature Medicine, 9(6), 669–676. https://doi.org/10.1038/nm0603-669CrossRefPubMed

81.

Pugh, C. W., & Ratcliffe, P. J. (2003). Regulation of angiogenesis by hypoxia: Role of the HIF system. Nature Medicine, 9(6), 677–684. https://doi.org/10.1038/nm0603-677CrossRefPubMed

82.

Leith, J., & Michelson, S. (1995). Secretion rates and levels of vascular endothelial growth factor in clone A or HCT-8 human colon tumour cells as a function of oxygen concentration. Cell Proliferation, 28(8), 415–430. https://doi.org/10.1111/j.1365-2184.1995.tb00082.xCrossRefPubMed

83.

Kerbel, R. S. (2008). Tumor angiogenesis. New England Journal of Medicine, 358(19), 2039–2049. https://doi.org/10.1056/NEJMra0706596CrossRefPubMed

84.

Bergers, G., & Benjamin, L. E. (2003). Tumorigenesis and the angiogenic switch. Nature Reviews Cancer, 3(6), 401–410. https://doi.org/10.1038/nrc1093CrossRefPubMed

85.

Bayer, C., Shi, K., Astner, S. T., Maftei, C.-A., & Vaupel, P. (2011). Acute versus chronic hypoxia: Why a simplified classification is simply not enough. International Journal of Radiation Oncology, Biology, Physics, 80(4), 965–968. https://doi.org/10.1016/j.ijrobp.2011.02.049CrossRefPubMed

86.

MacLauchlan, S. C., Calabro, N. E., Huang, Y., Krishna, M., Bancroft, T., Sharma, T., et al. (2018). HIF-1α represses the expression of the angiogenesis inhibitor thrombospondin-2. Matrix Biology, 65, 45–58. https://doi.org/10.1016/j.matbio.2017.07.002CrossRefPubMed

87.

Sun, L.-L., Lei, F.-R., Jiang, X.-D., Du, X.-L., Xiao, L., Li, W.-D., et al. (2020). LncRNA GUSBP5-AS promotes EPC migration and angiogenesis and deep vein thrombosis resolution by regulating FGF2 and MMP2/9 through the miR-223-3p/FOXO1/Akt pathway. Aging (Albany NY), 12(5), 4506. https://doi.org/10.18632/aging.102904CrossRefPubMed

88.

Fukumura, D., & Jain, R. K. (2007). Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize. Journal of Cellular Biochemistry, 101(4), 937–949. https://doi.org/10.1002/jcb.21187CrossRefPubMed

89.

Vaupel, P. (1994). Blood flow, oxygenation, tissue pH distribution, and bioenergetic status of tumors: Ernst Schering Research Foundation, Information and Standards Med. https://doi.org/10.1007/978-1-4615-5865-1_29

90.

Milosevic, M., Fyles, A., Hedley, D., Pintilie, M., Levin, W., Manchul, L., et al. (2001). Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Research, 61(17), 6400–6405.

91.

Horsman, M. R., & Vaupel, P. (2016). Pathophysiological basis for the formation of the tumor microenvironment. Frontiers in Oncology, 6, 66. https://doi.org/10.3389/fonc.2016.00066CrossRefPubMedPubMedCentral

92.

Hall, J. E., & Hall, M. E. (2020). Guyton and Hall textbook of medical physiology e-Book. Elsevier Health Sciences.

93.

Boucher, Y., Baxter, L. T., & Jain, R. K. (1990). Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: Implications for therapy. Cancer Research, 50(15), 4478–4484.

94.

Molls, M., Anscher, M. S., Nieder, C., & Vaupel, P. (2009). The impact of tumor biology on cancer treatment and multidisciplinary strategies. Springer. https://doi.org/10.1007/978-3-540-74386-6CrossRef

95.

Sonveaux, P., Végran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., et al. (2008). Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. The Journal of Clinical Investigation, 118(12), 3930–3942. https://doi.org/10.1172/JCI36843CrossRefPubMedPubMedCentral

96.

Stubbs, M., McSheehy, P. M., Griffiths, J. R., & Bashford, C. L. (2000). Causes and consequences of tumour acidity and implications for treatment. Molecular Medicine Today, 6(1), 15–19. https://doi.org/10.1016/S1357-4310(99)01615-9CrossRefPubMed

97.

Gerweck, L. E. (1998). Tumor pH: Implications for treatment and novel drug design. Seminars in Radiation Oncology, 8(3), 176–182. https://doi.org/10.1016/S1053-4296(98)80043-X

98.

Wu, P., Gao, W., Su, M., Nice, E. C., Zhang, W., Lin, J., et al. (2021). Adaptive mechanisms of tumor therapy resistance driven by tumor microenvironment. Frontiers in Cell and Developmental Biology, 9, 641469. https://doi.org/10.3389/fcell.2021.641469CrossRefPubMedPubMedCentral

99.

Fontana, F., Anselmi, M., & Limonta, P. (2022). Molecular mechanisms of cancer drug resistance: Emerging biomarkers and promising targets to overcome tumor progression. Cancers (Basel), 14, 1614. https://doi.org/10.3390/cancers14071614CrossRefPubMed

100.

Qu, Y., Dou, B., Tan, H., Feng, Y., Wang, N., & Wang, D. (2019). Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment. Molecular Cancer, 18(1), 1–16. https://doi.org/10.1186/s12943-019-0992-4CrossRef

101.

Barker, H. E., Paget, J. T., Khan, A. A., & Harrington, K. J. (2015). The tumour microenvironment after radiotherapy: Mechanisms of resistance and recurrence. Nature Reviews Cancer, 15(7), 409–425. https://doi.org/10.1038/nrc3958CrossRefPubMedPubMedCentral

102.

Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013). Cancer drug resistance: An evolving paradigm. Nature Reviews Cancer, 13(10), 714–726. https://doi.org/10.1038/nrc3599CrossRefPubMed

103.

Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017). The different mechanisms of cancer drug resistance: A brief review. Advanced Pharmaceutical Bulletin, 7(3), 339. https://doi.org/10.15171/apb.2017.041CrossRefPubMedPubMedCentral

104.

Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., et al. (2014). Drug resistance in cancer: An overview. Cancers, 6(3), 1769–1792. https://doi.org/10.3390/cancers6031769CrossRefPubMedPubMedCentral

105.

Steinbichler, T. B., Dudás, J., Skvortsov, S., Ganswindt, U., Riechelmann, H., & Skvortsova, I.-I. (2018.) Therapy resistance mediated by cancer stem cells. Seminars in Cancer Biology, 53, 156–167. https://doi.org/10.1016/j.semcancer.2018.11.006

106.

Khalaf, K., Hana, D., Chou, J.T.-T., Singh, C., Mackiewicz, A., & Kaczmarek, M. (2021). Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Frontiers in Immunology, 12, 656364. https://doi.org/10.3389/fimmu.2021.656364CrossRefPubMedPubMedCentral

107.

Wu, T., & Dai, Y. (2017). Tumor microenvironment and therapeutic response. Cancer Letters, 387, 61–68. https://doi.org/10.1016/j.canlet.2016.01.043CrossRefPubMed

108.

Guo, Y., Wang, M., Zou, Y., Jin, L., Zhao, Z., Liu, Q., et al. (2022). Mechanisms of chemotherapeutic resistance and the application of targeted nanoparticles for enhanced chemotherapy in colorectal cancer. Journal of Nanobiotechnology, 20(1), 1–24. https://doi.org/10.1186/s12951-022-01586-4CrossRef

109.

Trédan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007). Drug resistance and the solid tumor microenvironment. Journal of the National Cancer Institute, 99(19), 1441–1454. https://doi.org/10.1093/jnci/djm135CrossRefPubMed

110.

Roma-Rodrigues, C., Mendes, R., Baptista, P. V., & Fernandes, A. R. (2019). Targeting tumor microenvironment for cancer therapy. International journal of Molecular Sciences, 20(4), 840. https://doi.org/10.3390/ijms20040840CrossRefPubMedPubMedCentral

111.

White, E. (2012). Deconvoluting the context-dependent role for autophagy in cancer. Nature Reviews Cancer, 12(6), 401–410. https://doi.org/10.1038/nrc3262CrossRefPubMedPubMedCentral

112.

Li, J., & Yuan, J. (2008). Caspases in apoptosis and beyond. Oncogene, 27(48), 6194–6206. https://doi.org/10.1038/onc.2008.297CrossRefPubMed

113.

Chen, L., Zeng, Y., & Zhou, S.-F. (2018). Role of Apoptosis in Cancer Resistance to Chemotherapy. In Current Understanding of Apoptosis—Programmed Cell Death. London, UK: IntechOpen Limited. https://doi.org/10.5772/intechopen.80056CrossRef

114.

Dogan, E., Kara, H. G., Kosova, B., & Cetintas, V. B. (2022). Targeting apoptosis to overcome chemotherapy resistance. In C. M. Sergi (Ed.), Metastasis. Exon Publications. https://doi.org/10.36255/exon-publications.metastasis.chemotherapy-resistance

115.

Xue, C., Xie, J., Zhao, D., Lin, S., Zhou, T., Shi, S., et al. (2017). The JAK/STAT 3 signalling pathway regulated angiogenesis in an endothelial cell/adipose-derived stromal cell co-culture, 3D gel model. Cell Proliferation, 50(1), e12307. https://doi.org/10.1111/cpr.12307CrossRefPubMed

116.

Tsao, S.-M., Hsia, T.-C., & Yin, M.-C. (2014). Protocatechuic acid inhibits lung cancer cells by modulating FAK, MAPK, and NF-κ B pathways. Nutrition and Cancer, 66(8), 1331–1341. https://doi.org/10.1080/01635581.2014.956259CrossRefPubMed

117.

de Bittencourt Pasquali, M. A., Gelain, D. P., Zeidán-Chuliá, F., Pires, A. S., Gasparotto, J., Terra, S. R., et al. (2013). Vitamin A (retinol) downregulates the receptor for advanced glycation endproducts (RAGE) by oxidant-dependent activation of p38 MAPK and NF-kB in human lung cancer A549 cells. Cellular Signalling, 25(4), 939–954. https://doi.org/10.1016/j.cellsig.2013.01.013CrossRefPubMed

118.

Chen, H.-X., Xu, X.-X., Zhang, Z., Tan, B.-Z., & Zhou, X.-D. (2017). MicroRNA-29b inhibits angiogenesis by targeting VEGFA through the MAPK/ERK and PI3K/Akt signaling pathways in endometrial carcinoma. Cellular Physiology and Biochemistry, 41(3), 933–946. https://doi.org/10.1159/000460510CrossRefPubMed

119.

Fakhri, S., Moradi, S. Z., DeLiberto, L. K., & Bishayee, A. (2022). Cellular senescence signaling in cancer: A novel therapeutic target to combat human malignancies. Biochemical Pharmacology, 199, 114989. https://doi.org/10.1016/j.bcp.2022.114989CrossRefPubMed

120.

Karthika, C., Sureshkumar, R., Zehravi, M., Akter, R., Ali, F., Ramproshad, S., et al. (2022). Multidrug resistance of cancer cells and the vital role of P-glycoprotein. Life (Basel), 12(6). https://doi.org/10.3390/life12060897

121.

Goebel, J., Chmielewski, J., & Hrycyna, C. A. (2021). The roles of the human ATP-binding cassette transporters P-glycoprotein and ABCG2 in multidrug resistance in cancer and at endogenous sites: Future opportunities for structure-based drug design of inhibitors. Cancer Drug Resist, 4(4), 784–804. https://doi.org/10.20517/cdr.2021.19CrossRefPubMedPubMedCentral

122.

Waghray, D., & Zhang, Q. (2018). Inhibit or evade multidrug resistance P-glycoprotein in cancer treatment. Journal of Medicinal Chemistry, 61(12), 5108–5121. https://doi.org/10.1021/acs.jmedchem.7b01457CrossRefPubMed

123.

Callaghan, R., Luk, F., & Bebawy, M. (2014). Inhibition of the multidrug resistance P-glycoprotein: Time for a change of strategy? Drug Metabolism and Disposition, 42(4), 623–631. https://doi.org/10.1124/dmd.113.056176CrossRefPubMedPubMedCentral

124.

Muz, B., de la Puente, P., Azab, F., & Azab, A. K. (2015). The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia, 3, 83. https://doi.org/10.2147/HP.S93413CrossRefPubMedPubMedCentral

125.

Majnooni, M. B., Fakhri, S., Smeriglio, A., Trombetta, D., Croley, C. R., Bhattacharyya, P., et al. (2019). Antiangiogenic effects of coumarins against cancer: From chemistry to medicine. Molecules, 24(23), 4278. https://doi.org/10.3390/molecules24234278CrossRefPubMedPubMedCentral

126.

Lugano, R., Ramachandran, M., & Dimberg, A. (2020). Tumor angiogenesis: Causes, consequences, challenges and opportunities. Cellular and Molecular Life Sciences, 77(9), 1745–1770. https://doi.org/10.1007/s00018-019-03351-7CrossRefPubMed

127.

Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., et al. (2019). Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Molecular Cancer, 18(1), 1–15. https://doi.org/10.1186/s12943-019-1089-9CrossRef

128.

Sevcikova, A., Izoldova, N., Stevurkova, V., Kasperova, B., Chovanec, M., Ciernikova, S., et al. (2022). The impact of the microbiome on resistance to cancer treatment with chemotherapeutic agents and immunotherapy. International Journal of Molecular Sciences, 23(1), 488. https://doi.org/10.3390/ijms23010488CrossRefPubMedPubMedCentral

129.

Garajová, I., Balsano, R., Wang, H., Leonardi, F., Giovannetti, E., Deng, D., et al. (2021). The role of the microbiome in drug resistance in gastrointestinal cancers. Expert Review of Anticancer Therapy, 21(2), 165–176. https://doi.org/10.1080/14737140.2021.1844007CrossRefPubMed

130.

Tang, L., Mei, Y., Shen, Y., He, S., Xiao, Q., Yin, Y., et al. (2021). Nanoparticle-mediated targeted drug delivery to remodel tumor microenvironment for cancer therapy. International Journal of Nanomedicine, 16, 5811. https://doi.org/10.2147/IJN.S321416CrossRefPubMedPubMedCentral

131.

Chen, Q., Liu, G., Liu, S., Su, H., Wang, Y., Li, J., et al. (2018). Remodeling the tumor microenvironment with emerging nanotherapeutics. Trends in Pharmacological Sciences, 39(1), 59–74. https://doi.org/10.1016/j.tips.2017.10.009CrossRefPubMed

132.

Martin, J. D., Miyazaki, T., & Cabral, H. (2021). Remodeling tumor microenvironment with nanomedicines. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 13(6). https://doi.org/10.1002/wnan.1730

133.

Mu, W., Chu, Q., Liu, Y., & Zhang, N. (2020). A review on nano-based drug delivery system for cancer chemoimmunotherapy. Nano-Micro Letters, 12(1), 1–24. https://doi.org/10.1007/s40820-020-00482-6CrossRef

134.

Raju, G. S. R., Pavitra, E., Varaprasad, G. L., Bandaru, S. S., Nagaraju, G. P., Farran, B., et al. (2022). Nanoparticles mediated tumor microenvironment modulation: Current advances and applications. Journal of Nanobiotechnology, 20(1), 274. https://doi.org/10.1186/s12951-022-01476-9CrossRefPubMedPubMedCentral

135.

Li, W., Du, Q., Li, X., Zheng, X., Lv, F., Xi, X., et al. (2020). Eriodictyol inhibits proliferation, metastasis and induces apoptosis of glioma cells via PI3K/Akt/NF-κB signaling pathway. Frontiers in Pharmacology, 11, 114. https://doi.org/10.3389/fphar.2020.00114CrossRefPubMedPubMedCentral

136.

Feyzizadeh, M., Barfar, A., Nouri, Z., Sarfraz, M., Zakeri-Milani, P., & Valizadeh, H. (2022). Overcoming multidrug resistance through targeting ABC transporters: Lessons for drug discovery. Expert Opinion on Drug Discovery, 17(9), 1013–1027. https://doi.org/10.1080/17460441.2022.2112666CrossRefPubMed

137.

Halder, J., Pradhan, D., Kar, B., Ghosh, G., & Rath, G. (2022). Nanotherapeutics approaches to overcome P-glycoprotein-mediated multi-drug resistance in cancer. Nanomedicine: Nanotechnology, Biology and Medicine, 40, 102494. https://doi.org/10.1016/j.nano.2021.102494

138.

Gao, S., Yang, D., Fang, Y., Lin, X., Jin, X., Wang, Q., et al. (2019). Engineering nanoparticles for targeted remodeling of the tumor microenvironment to improve cancer immunotherapy. Theranostics, 9(1), 126–151. https://doi.org/10.7150/thno.29431CrossRefPubMedPubMedCentral

139.

Joudeh, N., & Linke, D. (2022). Nanoparticle classification, physicochemical properties, characterization, and applications: A comprehensive review for biologists. Journal of Nanobiotechnology, 20(1), 262. https://doi.org/10.1186/s12951-022-01477-8CrossRefPubMedPubMedCentral

140.

Khan, I., Saeed, K., & Khan, I. (2019). Nanoparticles: Properties, applications and toxicities. Arabian Journal of Chemistry, 12(7), 908–931. https://doi.org/10.1016/j.arabjc.2017.05.011CrossRef

141.

Ealia, S. A. M., & Saravanakumar, M. (2017). A review on the classification, characterisation, synthesis of nanoparticles and their application. In IOP conference series: Materials science and engineering, (Vol. 263, pp. 032019, Vol. 3): IOP Publishing. https://doi.org/10.1088/1757-899X/263/3/032019

142.

Strambeanu, N., Demetrovici, L., Dragos, D., & Lungu, M. (2014). Nanoparticles: Definition, classification and general physical properties. In Nanoparticles’ promises and risks: characterization, manipulation, and potential hazards to humanity and the environment (pp. 3–8): Springer. https://doi.org/10.1007/978-3-319-11728-7_1

143.

Quinten, M. (2010). Optical properties of nanoparticle systems: Mie and beyond. Wiley. https://doi.org/10.1002/9783527633135CrossRef

144.

Kolhatkar, A. G., Jamison, A. C., Litvinov, D., Willson, R. C., & Lee, T. R. (2013). Tuning the magnetic properties of nanoparticles. International Journal of Molecular Sciences, 14(8), 15977–16009. https://doi.org/10.3390/ijms140815977CrossRefPubMedPubMedCentral

145.

Kibria, M., Anisur, M., Mahfuz, M., Saidur, R., & Metselaar, I. (2015). A review on thermophysical properties of nanoparticle dispersed phase change materials. Energy Conversion and Management, 95, 69–89. https://doi.org/10.1016/j.enconman.2015.02.028CrossRef

146.

Akbarzadeh, I., Shayan, M., Bourbour, M., Moghtaderi, M., Noorbazargan, H., Yeganeh, F. E., et al. (2021). Preparation, optimization and in-vitro evaluation of curcumin-loaded niosome@calcium alginate nanocarrier as a new approach for breast cancer treatment. Biology-Basel, 10(3). https://doi.org/10.3390/biology10030173

147.

Eskandari, Z., Bahadori, F., Yenigun, V. B., Demiray, M., Eroglu, M. S., Kocyigit, A., et al. (2021). Levan enhanced the NF-kappa B suppression activity of an oral nano PLGA-curcumin formulation in breast cancer treatment. International Journal of Biological Macromolecules, 189, 223–231. https://doi.org/10.1016/j.ijbiomac.2021.08.115CrossRefPubMed

148.

Karimpour, M., Feizi, M. A. H., Mahdavi, M., Krammer, B., Verwanger, T., Najafi, F., et al. (2019). Development of curcumin-loaded gemini surfactant nanoparticles: Synthesis, characterization and evaluation of anticancer activity against human breast cancer cell lines. Phytomedicine, 57, 183–190. https://doi.org/10.1016/j.phymed.2018.11.017CrossRefPubMed

149.

Wang, J., Wang, Y., Liu, Q., Yang, L. N., Zhu, R. R., Yu, C. Z., et al. (2016). Rational design of multifunctional dendritic mesoporous silica nanoparticles to load curcumin and enhance efficacy for breast cancer therapy. ACS Applied Materials & Interfaces, 8(40), 26511–26523. https://doi.org/10.1021/acsami.6b08400CrossRef

150.

Sahne, F., Mohammadi, M., & Najafpour, G. D. (2019). Single-layer assembly of multifunctional carboxymethylcellulose on graphene oxide nanoparticles for improving in vivo curcumin delivery into tumor cells. Acs Biomaterials Science & Engineering, 5(5), 2595–2609. https://doi.org/10.1021/acsbiomaterials.8b01628CrossRef

151.

Yallapu, M. M., Maher, D. M., Sundram, V., Bell, M. C., Jaggi, M., & Chauhan, S. C. (2010). Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. Journal of Ovarian Research, 3. https://doi.org/10.1186/1757-2215-3-11

152.

Alam, J., Dilnawaz, F., Sahoo, S. K., Singh, D. V., Mukhopadhyay, A. K., Hussain, T., et al. (2022). Curcumin Encapsulated into Biocompatible Co-Polymer PLGA Nanoparticle Enhanced Anti-Gastric Cancer and Anti-Helicobacter Pylori Effect. Asian Pacific Journal of Cancer Prevention, 23(1), 61–70. https://doi.org/10.31557/apjcp.2022.23.1.61CrossRefPubMedPubMedCentral

153.

Yallapu, M. M., Gupta, B. K., Jaggi, M., & Chauhan, S. C. (2010). Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. Journal of Colloid and Interface Science, 351(1), 19–29. https://doi.org/10.1016/j.jcis.2010.05.022CrossRefPubMed

154.

Ahmadi, F., Ghasemi-Kasman, M., Ghasemi, S., Tabari, M. G., Pourbagher, R., Kazemi, S., et al. (2017). Induction of apoptosis in HeLa cancer cells by an ultrasonic-mediated synthesis of curcumin-loaded chitosan-alginate-STPP nanoparticles. International Journal of Nanomedicine, 12, 8545–8556. https://doi.org/10.2147/ijn.S146516CrossRefPubMedPubMedCentral

155.

Al Moubarak, A., El Joumaa, M., Slika, L., Patra, D., & Borjac, J. (2021). Curcumin-polyallyhydrocarbon nanocapsules potently suppress 1,2-dimethylhydrazine-induced colorectal cancer in mice by inhibiting Wnt/β-catenin pathway. BioNanoScience, 11(2), 518–525. https://doi.org/10.1007/s12668-021-00842-5CrossRef

156.

Al-Ani, L. A., Kadir, F. A., Hashim, N. M., Julkapli, N. M., Seyfoddin, A., Lu, J., et al. (2020). The impact of curcumin-graphene based nanoformulation on cellular interaction and redox-activated apoptosis: An in vitro colon cancer study. Heliyon, 6(11). https://doi.org/10.1016/j.heliyon.2020.e05360

157.

Mardani, R., Hamblin, M. R., Taghizadeh, M., Banafshe, H. R., Nejati, M., Mokhtari, M., et al. (2020). Nanomicellar-curcumin exerts its therapeutic effects via affecting angiogenesis, apoptosis, and T cells in a mouse model of melanoma lung metastasis. Pathology Research and Practice, 216(9). https://doi.org/10.1016/j.prp.2020.153082

158.

Zaman, M. S., Chauhan, N., Yallapu, M. M., Gara, R. K., Maher, D. M., Kumari, S., et al. (2016). Curcumin nanoformulation for cervical cancer treatment. Scientific Reports, 6. https://doi.org/10.1038/srep20051

159.

Lee, W. H., Loo, C. Y., Ong, H. X., Traini, D., Young, P. M., & Rohanizadeh, R. (2016). Synthesis and characterization of inhalable flavonoid nanoparticle for lung cancer cell targeting. Journal of Biomedical Nanotechnology, 12(2), 371–386. https://doi.org/10.1166/jbn.2016.2162CrossRefPubMed

160.

Bisht, S., Feldmann, G., Soni, S., Ravi, R., Karikar, C., Maitra, A., et al. (2007). Polymeric nanoparticle-encapsulated curcumin (“nanocurcumin”): A novel strategy for human cancer therapy. Journal of Nanobiotechnology, 5, 3. https://doi.org/10.1186/1477-3155-5-3CrossRefPubMedPubMedCentral

161.

Lim, K. J., Bisht, S., Bar, E. E., Maitra, A., & Eberhart, C. G. (2011). A polymeric nanoparticle formulation of curcumin inhibits growth, clonogenicity and stem-like fraction in malignant brain tumors. Cancer Biology & Therapy, 11(5), 464–473. https://doi.org/10.4161/cbt.11.5.14410CrossRef

162.

Aghapour, F., Moghadamnia, A. A., Nicolini, A., Kani, S. N. M., Barari, L., Morakabati, P., et al. (2018). Quercetin conjugated with silica nanoparticles inhibits tumor growth in MCF-7 breast cancer cell lines. Biochemical and Biophysical Research Communications, 500(4), 860–865. https://doi.org/10.1016/j.bbrc.2018.04.174CrossRefPubMed

163.

Balakrishnan, S., Mukherjee, S., Das, S., Bhat, F. A., Singh, P. R., Patra, C. R., et al. (2017). Gold nanoparticles-conjugated quercetin induces apoptosis via inhibition of EGFR/PI3K/Akt-mediated pathway in breast cancer cell lines (MCF-7 and MDA-MB-231). Cell Biochemistry and Function, 35(4), 217–231. https://doi.org/10.1002/cbf.3266CrossRefPubMed

164.

Balakrishnan, S., Bhat, F. A., Singh, P., Mukherjee, S., Elumalai, P., Das, S., et al. (2016). Gold nanoparticle-conjugated quercetin inhibits epithelial-mesenchymal transition, angiogenesis and invasiveness via EGFR/VEGFR-2-mediated pathway in breast cancer. Cell Proliferation, 49(6), 678–697. https://doi.org/10.1111/cpr.12296CrossRefPubMedPubMedCentral

165.

Gulla, S., Reddy, V. C., Araveti, P. B., Lomada, D., Srivastava, A., Reddy, M. C., et al. (2022). Synthesis of titanium dioxide nanotubes (TNT) conjugated with quercetin and its in vivo antitumor activity against skin cancer. Journal of Molecular Structure, 1249. https://doi.org/10.1016/j.molstruc.2021.131556.

166.

Moon, H., Lertpatipanpong, P., Hong, Y., Kim, C. T., & Baek, S. J. (2021). Nano-encapsulated quercetin by soluble soybean polysaccharide/chitosan enhances anti-cancer, anti-inflammation, and anti-oxidant activities. Journal of Functional Foods, 87. https://doi.org/10.1016/j.jff.2021.104756.

167.

Mishra, S., Manna, K., Kayal, U., Saha, M., Chatterjee, S., Chandra, D., et al. (2020). Folic acid-conjugated magnetic mesoporous silica nanoparticles loaded with quercetin: A theranostic approach for cancer management. Rsc Advances, 10(39), 23148–23164. https://doi.org/10.1039/d0ra00664eCrossRefPubMedPubMedCentral

168.

Hu, K., Miao, L., Goodwin, T. J., Li, J., Liu, Q., & Huang, L. (2017). Quercetin remodels the tumor microenvironment to improve the permeation, retention, and antitumor effects of nanoparticles. ACS Nano, 11(5), 4916–4925. https://doi.org/10.1021/acsnano.7b01522CrossRefPubMedPubMedCentral

169.

Simon, A. T., Dutta, D., Chattopadhyay, A., & Ghosh, S. S. (2021). Quercetin-loaded luminescent hydroxyapatite nanoparticles for theranostic application in monolayer and spheroid cultures of cervical cancer cell line in vitro. ACS Applied Bio Materials, 4(5), 4495–4506. https://doi.org/10.1021/acsabm.1c00255CrossRefPubMed

170.

Alserihi, R. F., Mohammed, M. R. S., Kaleem, M., Khan, M. I., Sechi, M., Sanna, V., et al. (2022). Development of (-)-epigallocatechin-3-gallate-loaded folate receptor-targeted nanoparticles for prostate cancer treatment. Nanotechnology Reviews, 11(1), 298–311. https://doi.org/10.1515/ntrev-2022-0013CrossRef

171.

Siddiqui, I. A., Adhami, V. M., Bharali, D. J., Hafeez, B. B., Asim, M., Khwaja, S. I., et al. (2009). Introducing nanochemoprevention as a novel approach for cancer control: Proof of Principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Research, 69(5), 1712–1716. https://doi.org/10.1158/0008-5472.Can-08-3978CrossRefPubMedPubMedCentral

172.

Khan, N., Bharali, D. J., Adhami, V. M., Siddiqui, I. A., Cui, H. D., Shabana, S. M., et al. (2014). Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model. Carcinogenesis, 35(2), 415–423. https://doi.org/10.1093/carcin/bgt321CrossRefPubMed

173.

Zhang, Q., Liu, J., Liu, B., Xia, J., Chen, N., Chen, X., et al. (2014). Dihydromyricetin promotes hepatocellular carcinoma regression via a p53 activation-dependent mechanism. Scientific Reports, 4(1), 1–11. https://doi.org/10.1038/srep04628CrossRef

174.

Siddiqui, I. A., Bharali, D. J., Nihal, M., Adhami, V. M., Khan, N., Chamcheu, J. C., et al. (2014). Excellent anti-proliferative and pro-apoptotic effects of (-)-epigallocatechin-3-gallate encapsulated in chitosan nanoparticles on human melanoma cell growth both in vitro and in vivo. Nanomedicine-Nanotechnology Biology and Medicine, 10(8), 1619–1626. https://doi.org/10.1016/j.nano.2014.05.007CrossRefPubMed

175.

Wu, M., Jin, J. C., Jin, P., Xu, Y. Q., Yin, J. F., Qin, D. K., et al. (2017). Epigallocatechin gallate-beta-lactoglobulin nanoparticles improve the antitumor activity of EGCG for inducing cancer cell apoptosis. Journal of Functional Foods, 39, 257–263. https://doi.org/10.1016/j.jff.2017.10.038CrossRef

176.

de Pace, R. C. C., Liu, X. L., Sun, M., Nie, S. F., Zhang, J., Cai, Q. S., et al. (2013). Anticancer activities of (-)-epigallocatechin-3-gallate encapsulated nanoliposomes in MCF7 breast cancer cells. Journal of Liposome Research, 23(3), 187–196. https://doi.org/10.3109/08982104.2013.788023CrossRefPubMed

177.

Kazi, J., Sen, R., Ganguly, S., Jha, T., Ganguly, S., & Debnath, M. C. (2020). Folate decorated epigallocatechin-3-gallate (EGCG) loaded PLGA nanoparticles; in-vitro and in-vivo targeting efficacy against MDA-MB-231 tumor xenograft. International Journal of Pharmaceutics, 585. https://doi.org/10.1016/j.ijpharm.2020.119449.

178.

Alizadeh, L., Alizadeh, E., Zarebkohan, A., Ahmadi, E., Rahmati-Yamchi, M., & Salehi, R. (2020). AS1411 aptamer-functionalized chitosan-silica nanoparticles for targeted delivery of epigallocatechin gallate to the SKOV-3 ovarian cancer cell lines. Journal of Nanoparticle Research, 22(1). https://doi.org/10.1007/s11051-019-4735-7.

179.

Chen, B. H., Hsieh, C. H., Tsai, S. Y., Wang, C. Y., & Wang, C. C. (2020). Anticancer effects of epigallocatechin-3-gallate nanoemulsion on lung cancer cells through the activation of AMP-activated protein kinase signaling pathway. Scientific Reports, 10(1). https://doi.org/10.1038/s41598-020-62136-2.

180.

Hsieh, D. S., Wang, H., Tan, S. W., Huang, Y. H., Tsai, C. Y., Yeh, M. K., et al. (2011). The treatment of bladder cancer in a mouse model by epigallocatechin-3-gallate-gold nanoparticles. Biomaterials, 32(30), 7633–7640. https://doi.org/10.1016/j.biomaterials.2011.06.073CrossRefPubMed

181.

Di Leo, N., Battaglini, M., Berger, L., Giannaccini, M., Dente, L., Hampel, S., et al. (2017). A catechin nanoformulation inhibits WM266 melanoma cell proliferation, migration and associated neo-angiogenesis. European Journal of Pharmaceutics and Biopharmaceutics, 114, 1–10. https://doi.org/10.1016/j.ejpb.2016.12.024CrossRefPubMed

182.

Aldawsari, H. M., Alhakamy, N. A., Padder, R., Husain, M., & Shadab, M. (2020). Preparation and characterization of chitosan coated PLGA nanoparticles of resveratrol: Improved stability, antioxidant and apoptotic activities in H1299 Lung Cancer Cells. Coatings, 10(5). https://doi.org/10.3390/coatings10050439.

183.

Wang, X. C., Parvathaneni, V., Shukla, S. K., Kulkarni, N. S., Muth, A., Kunda, N. K., et al. (2020). Inhalable resveratrol-cyclodextrin complex loaded biodegradable nanoparticles for enhanced efficacy against non-small cell lung cancer. International Journal of Biological Macromolecules, 164, 638–650. https://doi.org/10.1016/j.ijbiomac.2020.07.124CrossRefPubMed

184.

Nassir, A. M., Shahzad, N., Ibrahim, I. A. A., Ahmad, I., Md, S., & Ain, M. R. (2018). Resveratrol-loaded PLGA nanoparticles mediated programmed cell death in prostate cancer cells. Saudi Pharmaceutical Journal, 26(6), 876–885. https://doi.org/10.1016/j.jsps.2018.03.009CrossRefPubMedPubMedCentral

185.

Inbaraj, B. S., Hua, L. H., & Chen, B. H. (2021). Comparative study on inhibition of pancreatic cancer cells by resveratrol gold nanoparticles and a resveratrol nanoemulsion prepared from grape skin. Pharmaceutics, 13(11). https://doi.org/10.3390/pharmaceutics13111871

186.

Xiang, S., Zhang, K. F., Yang, G. H., Gao, D. D., Zeng, C., & He, M. (2019). Mitochondria-targeted and resveratrol-loaded dual-function titanium disulfide nanosheets for photothermal-triggered tumor chemotherapy.Nanoscale Research Letters, 14. https://doi.org/10.1186/s11671-019-3044-5

187.

Tehrani, F. K., Ranji, N., Kouhkan, F., & Hosseinzadeh, S. (2020). Apoptosis induction and proliferation inhibition by silibinin encapsulated in nanoparticles in MIA PaCa-2 cancer cells and deregulation of some miRNAs. Iranian Journal of Basic Medical Sciences, 23(4), 469–482. https://doi.org/10.22038/ijbms.2020.39427.9349CrossRef

188.

Ramya, S., Thiruvenkataswamy, S., Kavithaa, K., Preethi, S., Winster, H., Balachander, V., et al. (2021). pH dependent drug release of silibinin, a polyphenol conjugated with magnetic nanoparticle against the human colon cancer cell. Journal of Cluster Science, 32(2), 305–317. https://doi.org/10.1007/s10876-020-01789-5CrossRef

189.

Pourgholi, A., Dadashpour, M., Mousapour, A., Firouzi Amandi, A., & Zarghami, N. (2021). Anticancer potential of silibinin loaded polymeric nanoparticles against breast cancer cells: Insight into the apoptotic genes targets. Asian Pacific Journal of Cancer Prevention, 22(8), 2587–2596. https://doi.org/10.31557/apjcp.2021.22.8.2587CrossRefPubMedPubMedCentral

190.

Rouholamini, S. E. Y., Moghassemi, S., Maharat, Z., Hakamivala, A., Kashanian, S., & Omidfar, K. (2018). Effect of silibinin-loaded nano-niosomal coated with trimethyl chitosan on miRNAs expression in 2D and 3D models of T47D breast cancer cell line. Artificial Cells Nanomedicine and Biotechnology, 46(3), 524–535. https://doi.org/10.1080/21691401.2017.1326928CrossRef

191.

Liu, Y., Xie, X. M., Hou, X. F., Shen, J. Y., Shi, J. P., Chen, H. Z., et al. (2020). Functional oral nanoparticles for delivering silibinin and cryptotanshinone against breast cancer lung metastasis. Journal of Nanobiotechnology, 18(1). https://doi.org/10.1186/s12951-020-00638-x

192.

Hossainzadeh, S., Ranji, N., Sohi, A. N., & Najafi, F. (2019). Silibinin encapsulation in polymersome: A promising anticancer nanoparticle for inducing apoptosis and decreasing the expression level of miR-125b/miR-182 in human breast cancer cells. Journal of Cellular Physiology, 234(12), 22285–22298. https://doi.org/10.1002/jcp.28795CrossRefPubMed

193.

Rajendran, I., Dhandapani, H., Anantanarayanan, R., & Rajaram, R. (2015). Apigenin mediated gold nanoparticle synthesis and their anti-cancer effect on human epidermoid carcinoma (A431) cells. RSC Advances, 5(63), 51055–51066. https://doi.org/10.1039/c5ra04303dCrossRef

194.

Jiang, J., Mao, Q. S., Li, H., & Lou, J. Q. (2017). Apigenin stabilized gold nanoparticles increased radiation therapy efficiency in lung cancer cells. International Journal of Clinical and Experimental Medicine, 10(9), 13298–13305.

195.

Sen, R., Ganguly, S., Ganguly, S., Debnath, M. C., Chakraborty, S., Mukherjee, B., et al. (2021). Apigenin-loaded PLGA-DMSA nanoparticles: A novel strategy to treat melanoma lung metastasis. Molecular Pharmaceutics, 18(5), 1920–1938. https://doi.org/10.1021/acs.molpharmaceut.0c00977CrossRefPubMed

196.

Raghavan, B. S., Kondath, S., Anantanarayanan, R., & Rajaram, R. (2015). Kaempferol mediated synthesis of gold nanoparticles and their cytotoxic effects on MCF-7 cancer cell line. Process Biochemistry, 50(11), 1966–1976. https://doi.org/10.1016/j.procbio.2015.08.003CrossRef

197.

Sulaiman, G. M., Waheeb, H. M., Jabir, M. S., Khazaal, S. H., Dewir, Y. H., & Naidoo, Y. (2020). Hesperidin loaded on gold nanoparticles as a drug delivery system for a successful biocompatible, anti-cancer, anti-inflammatory and phagocytosis inducer model. Scientific Reports, 10(1). https://doi.org/10.1038/s41598-020-66419-6

198.

Mi, X. J., Choi, H. S., Perumalsamy, H., Shanmugam, R., Thangavelu, L., Balusamy, S. R., et al. (2022). Biosynthesis and cytotoxic effect of silymarin-functionalized selenium nanoparticles induced autophagy mediated cellular apoptosis via downregulation of PI3K/Akt/mTOR pathway in gastric cancer. Phytomedicine, 99, 154014. https://doi.org/10.1016/j.phymed.2022.154014CrossRefPubMed

199.

Upadhyay, P., Bhattacharjee, M., Bhattacharya, S., Ahir, M., Adhikary, A., & Patra, P. (2020). Silymarin-loaded, lactobionic acid-conjugated porous PLGA nanoparticles induce apoptosis in liver cancer cells. Acs Applied Bio Materials, 3(10), 7178–7192. https://doi.org/10.1021/acsabm.0c00987CrossRefPubMed

200.

Abdelwahab, T. S., Abdelhamed, R. E., Ali, E. N., Mansour, N. A., & Abdalla, M. S. (2021). Evaluation of silver nanoparticles caffeic acid complex compound as new potential therapeutic agent against cancer incidence in mice. Asian Pacific Journal of Cancer Prevention, 22(10), 3189–3201. https://doi.org/10.31557/apjcp.2021.22.10.3189CrossRefPubMedPubMedCentral

201.

El-Gogary, R. I., Gaber, S. A. A., & Nasr, M. (2019). Polymeric nanocapsularbaicalin: Chemometric optimization, physicochemical characterization and mechanistic anticancer approaches on breast cancer cell lines. Scientific Reports, 9. https://doi.org/10.1038/s41598-019-47586-7

202.

Jo, J., Ko, W. K., & Lee, J. (2017). The effects of baicalin-conjugated gold nanoparticles for inducing apoptosis of cervical cancer cells. Journal of Nanoscience and Nanotechnology, 17(11), 8593–8597. https://doi.org/10.1166/jnn.2017.15175CrossRef

203.

Fang, F., Gong, C. Y., Qian, Z. Y., Zhang, X. N., Gou, M. L., You, C., et al. (2009). Honokiol nanoparticles in thermosensitive hydrogel: Therapeutic effects on malignant pleural effusion. ACS Nano, 3(12), 4080–4088. https://doi.org/10.1021/nn900785bCrossRefPubMed

204.

Godugu, C., Doddapaneni, R., & Singh, M. (2017). Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC). Colloids and Surfaces B-Biointerfaces, 153, 208–219. https://doi.org/10.1016/j.colsurfb.2017.01.038CrossRefPubMed

205.

Md, S., Alhakamy, N. A., Aldawsari, H. M., Husain, M., Kotta, S., Abdullah, S. T., et al. (2020). Formulation design, statistical optimization, and in vitro evaluation of a naringenin nanoemulsion to enhance apoptotic activity in A549 lung cancer cells. Pharmaceuticals, 13(7). https://doi.org/10.3390/ph13070152

206.

Badr, D. A., Amer, M. E., Abd-Elhay, W. M., Nasr, M. S. M., Abuamara, T. M. M., Ali, H., et al. (2019). Histopathological and genetic changes proved the anti-cancer potential of free and nano-capsulated sinapic acid. Applied Biological Chemistry, 62(1). https://doi.org/10.1186/s13765-019-0462-0

207.

Daduang, J., Palasap, A., Daduang, S., Boonsiri, P., Suwannalert, P., & Limpaiboon, T. (2015). Gallic acid enhancement of gold nanoparticle anticancer activity in cervical cancer cells. Asian Pacific Journal of Cancer Prevention, 16(1), 169–174. https://doi.org/10.7314/apjcp.2015.16.1.169CrossRefPubMed

208.

Maity, R., Chatterjee, M., Banerjee, A., Das, A., Mishra, R., Mazumder, S., et al. (2019). Gold nanoparticle-assisted enhancement in the anti-cancer properties of theaflavin against human ovarian cancer cells. Materials Science & Engineering C-Materials for Biological Applications, 104. https://doi.org/10.1016/j.msec.2019.109909

209.

Mariadoss, A. V. A., Vinayagam, R., Senthilkumar, V., Paulpandi, M., Murugan, K., Xu, B. J., et al. (2019). Phloretin loaded chitosan nanoparticles augments the pH-dependent mitochondrial-mediated intrinsic apoptosis in human oral cancer cells. International Journal of Biological Macromolecules, 130, 997–1008. https://doi.org/10.1016/j.ijbiomac.2019.03.031CrossRefPubMed

210.

Tousi, M. S., Sepehri, H., Khoee, S., Farimani, M. M., Delphi, L., & Mansourizadeh, F. (2021). Evaluation of apoptotic effects of mPEG-b-PLGA coated iron oxide nanoparticles as a eupatorin carrier on DU-145 and LNCaP human prostate cancer cell lines. Journal of Pharmaceutical Analysis, 11(1), 108–121. https://doi.org/10.1016/j.jpha.2020.04.002CrossRefPubMed

211.

Moradi, S. Z., Jalili, F., Farhadian, N., Joshi, T., Wang, M., Zou, L., et al. (2022). Polyphenols and neurodegenerative diseases: Focus on neuronal regeneration. Critical Reviews in Food Science and Nutrition, 62, 3421–3436. https://doi.org/10.1080/10408398.2020.1865870CrossRefPubMed

212.

Fakhri, S., Pesce, M., Patruno, A., Moradi, S. Z., Iranpanah, A., Farzaei, M. H., et al. (2020). Attenuation of Nrf2/Keap1/ARE in Alzheimer’s disease by plant secondary metabolites: A mechanistic review. Molecules, 25(21), 4926. https://doi.org/10.3390/molecules25214926CrossRefPubMedPubMedCentral

213.

Fakhri, S., Khodamorady, M., Naseri, M., Farzaei, M. H. & Khan, H. (2020). The ameliorating effects of anthocyanins on the cross-linked signaling pathways of cancer dysregulated metabolism. Pharmacological Research, 159, 104895. https://doi.org/10.1016/j.phrs.2020.104895

214.

Moradi, S. Z., Momtaz, S., Bayrami, Z., Farzaei, M. H., & Abdollahi, M. (2020). Nanoformulations of herbal extracts in treatment of neurodegenerative disorders. Frontiers in Bioengineering and Biotechnology, 8, 238. https://doi.org/10.3389/fbioe.2020.00238CrossRefPubMedPubMedCentral

215.

Fakhri, S., Iranpanah, A., Gravandi, M. M., Moradi, S. Z., Ranjbari, M., Majnooni, M. B., et al. (2021). Natural products attenuate PI3K/Akt/mTOR signaling pathway: A promising strategy in regulating neurodegeneration. Phytomedicine, 91, 153664. https://doi.org/10.1016/j.phymed.2021.153664CrossRefPubMed

216.

Karaboga Arslan, A. K., Uzunhisarcıklı, E., Yerer, M. B., & Bishayee, A. (2022). The golden spice curcumin in cancer: A perspective on finalized clinical trials during the last 10 years. Journal of Cancer Research and Therapeutics, 18(1), 19–26. https://doi.org/10.4103/jcrt.JCRT_1017_20CrossRefPubMed

217.

Nabavi, S. M., Russo, G. L., Tedesco, I., Daglia, M., Orhan, I. E., Nabavi, S. F., et al. (2018). Curcumin and melanoma: From chemistry to medicine. Nutrition and Cancer, 70(2), 164–175. https://doi.org/10.1080/01635581.2018.1412485CrossRefPubMed

218.

Fakhri, S., Abdian, S., Zarneshan, S. N., Moradi, S. Z., Farzaei, M. H., & Abdollahi, M. (2022). Nanoparticles in combating neuronal dysregulated signaling pathways: Recent approaches to the nanoformulations of phytochemicals and synthetic drugs against neurodegenerative diseases. International Journal of Nanomedicine, 17, 299. https://doi.org/10.2147/IJN.S347187CrossRefPubMedPubMedCentral

219.

Fakhri, S., Abbaszadeh, F., Jorjani, M., & Pourgholami, M. H. (2021). The effects of anticancer medicinal herbs on vascular endothelial growth factor based on pharmacological aspects: A review study. Nutrition and Cancer, 73(1), 1–15. https://doi.org/10.1080/01635581.2019.1673451

220.

Zarneshan, S. N., Fakhri, S., Bachtel, G., & Bishayee, A. (2023). Exploiting pivotal mechanisms behind the senescence-like cell cycle arrest in cancer. Advances in Protein Chemistry and Structural Biology, 1(135), 1–9. https://doi.org/10.1016/bs.apcsb.2022.11.007

221.

Fakhri, S., Nouri, Z., Moradi, S. Z., Akkol, E. K., Piri, S., Sobarzo-Sánchez, E., et al. (2021). Targeting multiple signal transduction pathways of sars-CoV-2: Approaches to COVID-19 therapeutic candidates. Molecules, 26(10), 2917. https://doi.org/10.3390/molecules26102917CrossRefPubMedPubMedCentral

222.

Fakhri, S., Piri, S., Moradi, S. Z., & Khan, H. (2022). Phytochemicals targeting oxidative stress, interconnected neuroinflammatory and neuroapoptotic pathways following radiation. Current Neuropharmacology, 20(5), 836–856. https://doi.org/10.2174/1570159X19666210809103346CrossRefPubMedPubMedCentral

223.

Fakhri, S., Gravandi, M. M., Abdian, S., Moradi, S. Z., & Echeverría, J. (2022). Quercetin derivatives in combating spinal cord injury: A mechanistic and systematic review. Life, 12(12), 1960. https://doi.org/10.3390/life12121960CrossRefPubMedPubMedCentral

224.

Khan, F., Niaz, K., Maqbool, F., Ismail Hassan, F., Abdollahi, M., Nagulapalli Venkata, K. C., et al. (2016). Molecular targets underlying the anticancer effects of quercetin: An update. Nutrients, 8(9). https://doi.org/10.3390/nu8090529

225.

Aggarwal, V., Tuli, H. S., Tania, M., Srivastava, S., Ritzer, E. E., Pandey, A., et al. (2022). Molecular mechanisms of action of epigallocatechin gallate in cancer: Recent trends and advancement. Seminars in Cancer Biology, 80, 256–275. https://doi.org/10.1016/j.semcancer.2020.05.011

226.

Datta, S., Ghosh, S., Bishayee, A., & Sinha, D. (2022). Flexion of Nrf2 by tea phytochemicals: A review on the chemopreventive and chemotherapeutic implications. Pharmacological Research, 182, 106319. https://doi.org/10.1016/j.phrs.2022.106319CrossRefPubMed

227.

Ghosh, P., Bag, S., Roy, A. S., Subramani, E., Chaudhury, K., & Dasgupta, S. (2016). Solubility enhancement of morin and epicatechin through encapsulation in an albumin based nanoparticulate system and their anticancer activity against the MDA-MB-468 breast cancer cell line. RSC Advances, 6(103), 101415–101429. https://doi.org/10.1039/c6ra20441dCrossRef

228.

Ahmad, I., Fakhri, S., Khan, H., Jeandet, P., Aschner, M. & Yu, Z. L. (2020). Targeting cell cycle by β-carboline alkaloids in vitro: Novel therapeutic prospects for the treatment of cancer. Chemico-Biological Interactions, 330, 109229. https://doi.org/10.1016/j.cbi.2020.109229

229.

Ko, J. H., Sethi, G., Um, J. Y., Shanmugam, M. K., Arfuso, F., Kumar, A. P., et al. (2017). The role of resveratrol in cancer therapy. International Journal of Molecular Sciences, 18(12). https://doi.org/10.3390/ijms18122589

230.

Öztürk, E., Arslan, A. K. K., Yerer, M. B., & Bishayee, A. (2017). Resveratrol and diabetes: A critical review of clinical studies. Biomedicine & Pharmacotherapy, 95, 230–234. https://doi.org/10.1016/j.biopha.2017.08.070CrossRef

231.

Tuli, H. S., Mittal, S., Aggarwal, D., Parashar, G., Parashar, N. C., Upadhyay, S. K., et al. (2021). Path of Silibinin from diet to medicine: A dietary polyphenolic flavonoid having potential anti-cancer therapeutic significance. Seminars in Cancer Biology, 73, 196–218. https://doi.org/10.1016/j.semcancer.2020.09.014CrossRefPubMed

232.

Rahmani, A. H., Alsahli, M. A., Almatroudi, A., Almogbel, M. A., Khan, A. A., Anwar, S., et al. (2022). The potential role of apigenin in cancer prevention and treatment. Molecules, 27(18). https://doi.org/10.3390/molecules27186051

233.

Qattan, M. Y., Khan, M. I., Alharbi, S. H., Verma, A. K., Al-Saeed, F. A., Abduallah, A. M., et al. (2022). Therapeutic importance of kaempferol in the treatment of cancer through the modulation of cell signalling pathways. Molecules, 27(24). https://doi.org/10.3390/molecules27248864

234.

Pandey, P., & Khan, F. (2021). A mechanistic review of the anticancer potential of hesperidin, a natural flavonoid from citrus fruits. Nutrition Research, 92, 21–31. https://doi.org/10.1016/j.nutres.2021.05.011CrossRefPubMed

235.

Mirzaei, S., Gholami, M. H., Zabolian, A., Saleki, H., Farahani, M. V., Hamzehlou, S., et al. (2021). Caffeic acid and its derivatives as potential modulators of oncogenic molecular pathways: New hope in the fight against cancer. Pharmacological Research, 171, 105759. https://doi.org/10.1016/j.phrs.2021.105759CrossRefPubMed

236.

Banik, K., Khatoon, E., Harsha, C., Rana, V., Parama, D., Thakur, K. K., et al. (2022). Wogonin and its analogs for the prevention and treatment of cancer: A systematic review. Phytotherapy Research, 36(5), 1854–1883. https://doi.org/10.1002/ptr.7386CrossRefPubMed

237.

Singh, S., Meena, A., & Luqman, S. (2021). Baicalin mediated regulation of key signaling pathways in cancer. Pharmacological Research, 164, 105387. https://doi.org/10.1016/j.phrs.2020.105387

238.

Ghimire, G. P., Koirala, N., Pandey, R. P., Jung, H. J., & Sohng, J. K. (2015). Modification of emodin and aloe-emodin by glycosylation in engineered Escherihia coli. World Journal of Microbiology and Biotechnology, 31(4), 611–619. https://doi.org/10.1007/s11274-015-1815-4CrossRefPubMed

239.

Akkol, E. K., Tatlı, II, Karatoprak, G., Ağar, O. T., Yücel, Ç., Sobarzo-Sánchez, E., et al. (2021). Is emodin with anticancer effects completely innocent? Two sides of the coin. Cancers (Basel), 13(11). https://doi.org/10.3390/cancers13112733

240.

Khatoon, F., Ali, S., Kumar, V., Elasbali, A. M., Alhassan, H. H., Alharethi, S. H., et al. (2022). Pharmacological features, health benefits and clinical implications of honokiol. Journal of Biomolecular Structure and Dynamics, 1–23. https://doi.org/10.1080/07391102.2022.2120541

241.

Rauf, A., Olatunde, A., Imran, M., Alhumaydhi, F. A., Aljohani, A. S. M., Khan, S. A., et al. (2021). Honokiol: A review of its pharmacological potential and therapeutic insights. Phytomedicine, 90, 153647. https://doi.org/10.1016/j.phymed.2021.153647CrossRefPubMed

242.

Ansari, I. A., & Akhtar, M. S. (2019). Current insights on the role of terpenoids as anticancer agents: A perspective on cancer prevention and treatment. In Natural Bio-active Compounds (pp. 53–80): Springer. https://doi.org/10.1007/978-981-13-7205-6_3

243.

Huang, M., Lu, J.-J., Huang, M.-Q., Bao, J.-L., Chen, X.-P., & Wang, Y.-T. (2012). Terpenoids: Natural products for cancer therapy. Expert Opinion on Investigational Drugs, 21(12), 1801–1818. https://doi.org/10.1517/13543784.2012.727395CrossRefPubMed

244.

Perveen, S., & Al-Taweel, A. (2018). Terpenes and terpenoids. BoD–Books on Demand. https://doi.org/10.5772/intechopen.71175

245.

Yan, Z. K., Wang, Q. T., Liu, X. L., Peng, J., Li, Q., Wu, M., et al. (2018). Cationic nanomicelles derived from Pluronic F127 as delivery vehicles of Chinese herbal medicine active components of ursolic acid for colorectal cancer treatment. Rsc Advances, 8(29), 15906–15914. https://doi.org/10.1039/c8ra01071dCrossRefPubMedPubMedCentral

246.

Fan, L. L., Zhang, B. C., Xu, A. C., Shen, Z. C., Guo, Y., Zhao, R. R., et al. (2018). Carrier-free, pure nanodrug formed by the self-assembly of an anticancer drug for cancer immune therapy. Molecular Pharmaceutics, 15(6), 2466–2478. https://doi.org/10.1021/acs.molpharmaceut.8b00444CrossRefPubMed

247.

Sharma, M., Sharma, S., Sharma, V., Sharma, K., Yadav, S. K., Dwivedi, P., et al. (2017). Oleanolic-bioenhancer coloaded chitosan modified nanocarriers attenuate breast cancer cells by multimode mechanism and preserve female fertility. International Journal of Biological Macromolecules, 104, 1345–1358. https://doi.org/10.1016/j.ijbiomac.2017.06.005CrossRefPubMed

248.

Bao, X., Gao, M., Xu, H., Liu, K. X., Zhang, C. H., Jiang, N., et al. (2015). A novel oleanolic acid-loaded PLGA-TPGS nanoparticle for liver cancer treatment. Drug Development and Industrial Pharmacy, 41(7), 1193–1203. https://doi.org/10.3109/03639045.2014.938081CrossRefPubMed

249.

Huang, Y., Chen, Y., Shaw, A. M., Goldfine, H., Tian, J. Q., & Cai, J. Y. (2018). Enhancing TFEB-mediated cellular degradation pathways by the mTORC1 inhibitor quercetin.Oxidative Medicine and Cellular Longevity, 2018. https://doi.org/10.1155/2018/5073420

250.

Zhang, X. F., Huang, F. H., Zhang, G. L., Bai, D. P., Massimo, D. F., Huang, Y. F., et al. (2017). Novel biomolecule lycopene-reduced graphene oxide-silver nanoparticle enhances apoptotic potential of trichostatin A in human ovarian cancer cells (SKOV3). International Journal of Nanomedicine, 12, 7551–7575. https://doi.org/10.2147/ijn.S144161CrossRefPubMedPubMedCentral

251.

Kundu, M., Chatterjee, S., Ghosh, N., Manna, P., Das, J., & Sil, P. C. (2020). Tumor targeted delivery of umbelliferone via a smart mesoporous silica nanoparticles controlled-release drug delivery system for increased anticancer efficiency. Materials Science & Engineering C-Materials for Biological Applications, 116. https://doi.org/10.1016/j.msec.2020.111239

252.

Wang, C., Shan, Y., Yang, J. L., Xu, X. L., Zhuang, B., Fan, Y. F., et al. (2015). Inhibition of cancer angiogenesis using triptolide nanoparticles. Journal of Biomedical Nanotechnology, 11(5), 805–815. https://doi.org/10.1166/jbn.2015.2016CrossRefPubMed

253.

Gowda, R., Madhunapantula, S. V., Sharma, A., Kuzu, O. F., & Robertson, G. P. (2014). Nanolipolee-007, a novel nanoparticle-based drug containing leelamine for the treatment of melanoma. Molecular Cancer Therapeutics, 13(10), 2328–2340. https://doi.org/10.1158/1535-7163.Mct-14-0357CrossRefPubMedPubMedCentral

254.

Asasutjarit, R., Sooksai, N., Fristiohady, A., Lairungruang, K., Ng, S. F., & Fuongfuchat, A. (2021). Optimization of production parameters for andrographolide-loaded nanoemulsion preparation by microfluidization and evaluations of its bioactivities in skin cancer cells and UVB radiation-exposed skin. Pharmaceutics, 13(8). https://doi.org/10.3390/pharmaceutics13081290

255.

Wang, J., Song, Y. H., Zhang, M. X., Wu, Z. S., Xu, Y. J., Lin, J., et al. (2019). A liposomal curcumol nanocomposite for magnetic resonance imaging and endoplasmic reticulum stress-mediated chemotherapy of human primary ovarian cancer. Journal of Materials Chemistry B, 7(18), 2938–2947. https://doi.org/10.1039/c8tb03123aCrossRef

256.

Chen, X., Yin, T., Zhang, B., Sun, B., Chen, J., Xiao, T., et al. (2020). Inhibitory effects of brusatol delivered using glycosaminoglycan-placental chondroitin sulfate A-modified nanoparticles on the proliferation, migration and invasion of cancer cells. International Journal of Molecular Medicine, 46(2), 817–827. https://doi.org/10.3892/ijmm.2020.4627CrossRefPubMedPubMedCentral

257.

Kumar, P., Singh, A. K., Raj, V., Rai, A., Keshari, A. K., Kumar, D., et al. (2018). Poly(lactic-co-glycolic acid)-loaded nanoparticles of betulinic acid for improved treatment of hepatic cancer: Characterization, in vitro and in vivo evaluations. International Journal of Nanomedicine, 13, 975–990. https://doi.org/10.2147/ijn.S157391CrossRefPubMedPubMedCentral

258.

Mehta, M., Malyla, V., Paudel, K. R., Chellappan, D. K., Hansbro, P. M., Oliver, B. G., et al. (2021). Berberine loaded liquid crystalline nanostructure inhibits cancer progression in adenocarcinomic human alveolar basal epithelial cells in vitro. Journal of Food Biochemistry, 45(11). https://doi.org/10.1111/jfbc.13954

259.

Chiu, C. F., Fu, R. H., Hsu, S. H., Yu, Y. H., Yang, S. F., Tsao, T. C. Y., et al. (2021). Delivery capacity and anticancer ability of the berberine-loaded gold nanoparticles to promote the apoptosis effect in breast cancer. Cancers, 13(21). https://doi.org/10.3390/cancers13215317

260.

Loo, Y. S., Madheswaran, T., Rajendran, R., & Bose, R. J. C. (2020). Encapsulation of berberine into liquid crystalline nanoparticles to enhance its solubility and anticancer activity in MCF7 human breast cancer cells. Journal of Drug Delivery Science and Technology, 57. https://doi.org/10.1016/j.jddst.2020.101756

261.

Bhanumathi, R., Manivannan, M., Thangaraj, R., & Kannan, S. (2018). Drug-carrying capacity and anticancer effect of the folic acid-and berberine-loaded silver nanomaterial to regulate the AKT-ERK pathway in breast cancer. ACS Omega, 3(7), 8317–8328. https://doi.org/10.1021/acsomega.7b01347CrossRefPubMedPubMedCentral

262.

Bhanumathi, R., Vimala, K., Shanthi, K., Thangaraj, R., & Kannan, S. (2017). Bioformulation of silver nanoparticles as berberine carrier cum anticancer agent against breast cancer. New Journal of Chemistry, 41(23), 14466–14477. https://doi.org/10.1039/c7nj02531aCrossRef

263.

Grebinyk, A., Yashchuk, V., Bashmakova, N., Gryn, D., Hagemann, T., Naumenko, A., et al. (2019). A new triple system DNA-Nanosilver-Berberine for cancer therapy. Applied Nanoscience, 9(5), 945–956. https://doi.org/10.1007/s13204-018-0688-xCrossRef

264.

Rad, J. G., & Hoskin, D. W. (2020). Delivery of apoptosis-inducing piperine to triple-negative breast cancer cells via co-polymeric nanoparticles. Anticancer Research, 40(2), 689–694. https://doi.org/10.21873/anticanres.13998CrossRefPubMed

265.

Pachauri, M., Gupta, E. D., & Ghosh, P. C. (2015). Piperine loaded PEG-PLGA nanoparticles: Preparation, characterization and targeted delivery for adjuvant breast cancer chemotherapy. Journal of Drug Delivery Science and Technology, 29, 269–282. https://doi.org/10.1016/j.jddst.2015.08.009CrossRef

266.

Li, X. L., Zhen, D. H., Lu, X. W., Xu, H. E., Shao, Y., Xue, Q. P., et al. (2010). Enhanced cytotoxicity and activation of ROS-dependent c-Jun NH2-terminal kinase and caspase-3 by low doses of tetrandrine-loaded nanoparticles in Lovo cells - A possible Trojan strategy against cancer. European Journal of Pharmaceutics and Biopharmaceutics, 75(3), 334–340. https://doi.org/10.1016/j.ejpb.2010.04.016CrossRefPubMed

267.

Li, C. P., Cai, G., Song, D. Q., Gao, R. X., Teng, P., Zhou, L. H., et al. (2019). Development of EGFR-targeted evodiamine nanoparticles for the treatment of colorectal cancer. Biomaterials Science, 7(9), 3627–3639. https://doi.org/10.1039/c9bm00613cCrossRefPubMed

268.

Chen, M. Y., Xiong, F., Ma, L., Yao, H., Wang, Q. R., Wen, L. J., et al. (2016). Inhibitory effect of magnetic Fe3O4 nanoparticles coloaded with homoharringtonine on human leukemia cells in vivo and in vitro. International Journal of Nanomedicine, 11, 4413–4422. https://doi.org/10.2147/ijn.S105543CrossRefPubMedPubMedCentral

269.

Saeed, L. M., Mahmood, M., Xu, Y., Nima, Z. A., Kannarpady, G. K., Bratton, S. M., et al. (2015). Nanodelivery of gambogic acid by functionalized graphene enhances inhibition of cell proliferation and induces G(0)/G(1) cell cycle arrest in cervical, ovarian, and prostate cancer cells. Rsc Advances, 5(55), 44022–44030. https://doi.org/10.1039/c5ra00833fCrossRef

270.

Verma, R. K., Yu, W., Singh, S. P., Shankar, S., & Srivastava, R. K. (2015). Anthothecol-encapsulated PLGA nanoparticles inhibit pancreatic cancer stem cell growth by modulating sonic hedgehog pathway. Nanomedicine-Nanotechnology Biology and Medicine, 11(8), 2061–2070. https://doi.org/10.1016/j.nano.2015.07.001CrossRefPubMed

271.

Shin, S. W., Jung, W., Choi, C., Kim, S. Y., Son, A., Kim, H., et al. (2018). Fucoidan-manganese dioxide nanoparticles potentiate radiation therapy by co-targeting tumor hypoxia and angiogenesis. Marine Drugs, 16(12). https://doi.org/10.3390/md16120510

272.

Li, S. S., Zhang, F. Z., Yu, Y., & Zhang, Q. X. (2020). A dermatan sulfate-functionalized biomimetic nanocarrier for melanoma targeted chemotherapy. Carbohydrate Polymers, 235. https://doi.org/10.1016/j.carbpol.2020.115983

273.

Khuda-Bukhsh, A. R., Bhattacharyya, S. S., Paul, S., & Boujedaini, N. (2010). Polymeric nanoparticle encapsulation of a naturally occurring plant scopoletin and its effects on human melanoma cell A375. Zhong Xi Yi Jie He Xue Bao, 8(9), 853–862. https://doi.org/10.3736/jcim20100909CrossRefPubMed

274.

Shanmugam, M. K., Dai, X., Kumar, A. P., Tan, B. K., Sethi, G., & Bishayee, A. (2013). Ursolic acid in cancer prevention and treatment: Molecular targets, pharmacokinetics and clinical studies. Biochemical Pharmacology, 85(11), 1579–1587. https://doi.org/10.1016/j.bcp.2013.03.006CrossRefPubMed

275.

Zafar, S., Khan, K., Hafeez, A., Irfan, M., Armaghan, M., Rahman, A. U., et al. (2022). Ursolic acid: A natural modulator of signaling networks in different cancers. Cancer Cell International, 22(1), 399. https://doi.org/10.1186/s12935-022-02804-7CrossRefPubMedPubMedCentral

276.

Mohtashami, L., Ghows, N., Tayarani-Najaran, Z., & Iranshahi, M. (2019). Galbanic acid-coated Fe3O4 magnetic nanoparticles with enhanced cytotoxicity to prostate cancer cells. Planta Medica, 85(2), 169–178. https://doi.org/10.1055/a-0721-1886CrossRefPubMed

277.

Li, H. J., Liu, Z., Deng, X. R., Lin, J., Ma, P. A., & Teng, B. (2018). Preparation and in vitro anti-laryngeal cancer evaluation of protopanaxadiol-loaded hollow gold nanoparticles. Chinese Journal of Analytical Chemistry, 46(5), 716–722. https://doi.org/10.1016/s1872-2040(18)61087-4CrossRef

278.

Fakhri, S., Abbaszadeh, F., Moradi, S. Z., Cao, H., Khan, H., & Xiao, J. (2022). Effects of polyphenols on oxidative stress, inflammation, and interconnected pathways during spinal cord injury. Oxidative Medicine and Cellular Longevity, 2022, 1. https://doi.org/10.1155/2022/8100195CrossRef

279.

Mondal, A., Gandhi, A., Fimognari, C., Atanasov, A. G., & Bishayee, A. (2019). Alkaloids for cancer prevention and therapy: Current progress and future perspectives. European Journal of Pharmacology, 858, 172472. https://doi.org/10.1016/j.ejphar.2019.172472CrossRefPubMed

280.

Hou, Q., He, W.-J., Wu, Y.-S., Hao, H.-J., Xie, X.-Y., & Fu, X.-B. (2020). Berberine: A traditional natural product with novel biological activities. Alternative Therapies in Health & Medicine, 26, 20–27.

281.

Liu, D., Meng, X., Wu, D., Qiu, Z., & Luo, H. (2019). A natural isoquinoline alkaloid with antitumor activity: Studies of the biological activities of berberine. Frontiers in Pharmacology, 10, 9. https://doi.org/10.3389/fphar.2019.00009CrossRefPubMedPubMedCentral

282.

Nechepurenko, I., Salakhutdinov, N., & Tolstikov, G. (2010). Berberine: Chemistry and biological activity. Chemistry for Sustainable Development, 18, 1–23.

283.

Och, A., Podgórski, R., & Nowak, R. (2020). Biological activity of berberine—a summary update. Toxins, 12(11), 713. https://doi.org/10.3390/toxins12110713CrossRefPubMedPubMedCentral

284.

Geetha, T., Kapila, M., Prakash, O., Deol, P. K., Kakkar, V., & Kaur, I. P. (2015). Sesamol-loaded solid lipid nanoparticles for treatment of skin cancer. Journal of Drug Targeting, 23(2), 159–169. https://doi.org/10.3109/1061186x.2014.965717CrossRefPubMed

285.

Sun, Q., Teong, B., Chen, I. F., Chang, S. J., Gao, J. M., & Kuo, S. M. (2014). Enhanced apoptotic effects of dihydroartemisinin-aggregated gelatin and hyaluronan nanoparticles on human lung cancer cells. Journal of Biomedical Materials Research Part B-Applied Biomaterials, 102(3), 455–462. https://doi.org/10.1002/jbm.b.33023CrossRefPubMed

286.

Song, W., Anselmo, A. C., & Huang, L. (2019). Nanotechnology intervention of the microbiome for cancer therapy. Nature Nanotechnology, 14(12), 1093–1103. https://doi.org/10.1038/s41565-019-0589-5CrossRefPubMed

287.

Ghanbari-Movahed, M., Kaceli, T., Mondal, A., Farzaei, M. H., & Bishayee, A. (2021). Recent advances in improved anticancer efficacies of camptothecin nano-formulations: A systematic review. Biomedicines, 9(5), 480. https://doi.org/10.3390/biomedicines9050480CrossRefPubMedPubMedCentral

288.

Hu, Y. L., Zhang, L. M., Wang, H., Xu, S., Mujeeb, A., Nie, G. J., et al. (2017). Biological effects of amphiphilic copolymer nanoparticle-encapsulated multi- target chemotherapeutic drugs on MCF-7 human breast cancer cells. Metabolomics, 13(5). https://doi.org/10.1007/s11306-017-1187-x

289.

Pawar, V. K., Singh, Y., Sharma, K., Shrivastav, A., Sharma, A., Singh, A., et al. (2019). Improved chemotherapy against breast cancer through immunotherapeutic activity of fucoidan decorated electrostatically assembled nanoparticles bearing doxorubicin. International Journal of Biological Macromolecules, 122, 1100–1114. https://doi.org/10.1016/j.ijbiomac.2018.09.059CrossRefPubMed

290.

Varukattu, N. B., Vivek, R., Rejeeth, C., Thangam, R., Ponraj, T., Sharma, A., et al. (2020). Nanostructured pH-responsive biocompatible chitosan coated copper oxide nanoparticles: A polymeric smart intracellular delivery system for doxorubicin in breast cancer cells. Arabian Journal of Chemistry, 13(1), 2276–2286. https://doi.org/10.1016/j.arabjc.2018.04.012CrossRef

291.

Wang, Q., Zhong, Y. N., Liu, W. T., Wang, Z. M., Gu, L. Q., Li, X. J., et al. (2019). Enhanced chemotherapeutic efficacy of the low-dose doxorubicin in breast cancer via nanoparticle delivery system crosslinked hyaluronic acid. Drug Delivery, 26(1), 12–22. https://doi.org/10.1080/10717544.2018.1507057CrossRefPubMedPubMedCentral

292.

Wang, Z. G., Zhang, R. X., Zhang, T., He, C. S., He, R., Ju, X. R., et al. (2018). In situ proapoptotic peptide-generating rapeseed protein-based nanocomplexes synergize chemotherapy for cathepsin-B overexpressing breast cancer. ACS Applied Materials & Interfaces, 10(48), 41056–41069. https://doi.org/10.1021/acsami.8b14001CrossRef

293.

Long, J. T., Cheang, T. Y., Zhuo, S. Y., Zeng, R. F., Dai, Q. S., Li, H. P., et al. (2014). Anticancer drug-loaded multifunctional nanoparticles to enhance the chemotherapeutic efficacy in lung cancer metastasis. Journal of Nanobiotechnology, 12. https://doi.org/10.1186/s12951-014-0037-5

294.

Ramya, A. N., Joseph, M. M., Maniganda, S., Karunakaran, V., Sreelekha, T. T., & Maiti, K. K. (2021). Emergence of gold-mesoporous silica hybrid nanotheranostics: Dox-encoded, folate targeted chemotherapy with modulation of SERS fingerprinting for apoptosis toward tumor eradication (vol 13, 1700819, 2017). Small, 17(2). https://doi.org/10.1002/smll.202007852

295.

Quinto, C. A., Mohindra, P., Tong, S., & Bao, G. (2015). Multifunctional superparamagnetic iron oxide nanoparticles for combined chemotherapy and hyperthermia cancer treatment. Nanoscale, 7(29), 12728–12736. https://doi.org/10.1039/c5nr02718gCrossRefPubMedPubMedCentral

296.

Pan, D. C., Krishnan, V., Salinas, A. K., Kim, J., Sun, T., Ravid, S., et al. (2021). Hyaluronic acid-doxorubicin nanoparticles for targeted treatment of colorectal cancer. Bioengineering & Translational Medicine, 6(1). https://doi.org/10.1002/btm2.10166

297.

Assy, L., Gemeay, A., Gomaa, S., Aldubayan, M. A., & Salem, M. L. (2020). Impact of graphene oxide nano sheets loaded with chemotherapeutic drug on tumor cells. Journal of Nanoparticle Research, 22(4). https://doi.org/10.1007/s11051-020-04790-1

298.

Contreras-Caceres, R., Leiva, M., Ortiz, R., Diaz, A., Perazzoli, G., Casado-Rodriguez, M., et al. (2017). Paclitaxel-loaded hollow-poly(4-vinylpyridine) nanoparticles enhance drug chemotherapeutic efficacy in lung and breast cancer cell lines. Nano Research, 10(3), 856–875. https://doi.org/10.1007/s12274-016-1340-2CrossRef

299.

Divya, M., Maiti, S. K., Sangeetha, P., Shivaraju, S., Kumar, N., Tiwari, A. K., et al. (2019). Evaluation of chemotherapy with nanosomal paclitaxel and gene therapy expressing apoptosis-inducing proteins in the management of spontaneous canine mammary neoplasm. Journal of Stem Cells & Regenerative Medicine, 15(2), 24–34. https://doi.org/10.46582/jsrm.1502007CrossRef

300.

Shao, W., Paul, A., Zhao, B., Lee, C., Rodes, L., & Prakash, S. (2013). Carbon nanotube lipid drug approach for targeted delivery of a chemotherapy drug in a human breast cancer xenograft animal model. Biomaterials, 34(38), 10109–10119. https://doi.org/10.1016/j.biomaterials.2013.09.007CrossRefPubMed

301.

Ullah, I., Chung, K., Bae, S., Li, Y., Kim, C., Choi, B., et al. (2020). Nose-to-brain delivery of cancer-targeting paclitaxel-loaded nanoparticles potentiates antitumor effects in malignant glioblastoma. Molecular Pharmaceutics, 17(4), 1193–1204. https://doi.org/10.1021/acs.molpharmaceut.9b01215CrossRefPubMed

302.

Yan, C. Y., Shi, W. G., Gu, J. W., Lee, R. J., & Zhang, Y. (2021). Design of a novel nucleus-targeted NLS-KALA-SA nanocarrier to delivery poorly water-soluble anti-tumor drug for lung cancer treatment. Journal of Pharmaceutical Sciences, 110(6), 2432–2441. https://doi.org/10.1016/j.xphs.2020.12.034CrossRefPubMed

303.

Zhao, X. F., Fan, J., Wu, P., Wei, C. M., Chen, Q. Y., Ming, Z., et al. (2019). Chronic chemotherapy with paclitaxel nanoparticles induced apoptosis in lung cancer in vitro and in vivo. International Journal of Nanomedicine, 14, 1299–1309. https://doi.org/10.2147/ijn.S188049CrossRefPubMedPubMedCentral

304.

Huang, J. Y., Chen, M. H., Kuo, W. T., Sun, Y. J., & Lin, F. H. (2015). The characterization and evaluation of cisplatin-loaded magnetite-hydroxyapatite nanoparticles (mHAp/CDDP) as dual treatment of hyperthermia and chemotherapy for lung cancer therapy. Ceramics International, 41(2), 2399–2410. https://doi.org/10.1016/j.ceramint.2014.10.054CrossRef

305.

Luo, J., Zhong, X., Peng, Y., Hao, C., Liang, X., Yang, Y., et al. (2022). Self-anti-angiogenesis nanoparticles enhance anti-metastatic-tumor efficacy of chemotherapeutics. Bioactive Materials, 13, 179–190. https://doi.org/10.1016/j.bioactmat.2021.10.037CrossRefPubMed

306.

Tang, Q. S., & Chen, D. Z. (2014). Study of the therapeutic effect of 188Re labeled folate targeting albumin nanoparticle coupled with cis-Diamminedichloroplatinum Cisplatin on human ovarian cancer. Bio-Medical Materials and Engineering, 24(1), 711–722. https://doi.org/10.3233/bme-130859CrossRefPubMed

307.

Zhao, X. X., Pan, J. H., Li, W., Yang, W. D., Qin, L., & Pan, Y. L. (2018). Gold nanoparticles enhance cisplatin delivery and potentiate chemotherapy by decompressing colorectal cancer vessels. International Journal of Nanomedicine, 13, 6207–6221. https://doi.org/10.2147/ijn.S176928CrossRefPubMedPubMedCentral

308.

Farhana, A., Koh, A. E., Kothandan, S., Alsrhani, A., Mok, P. L., & Subbiah, S. K. (2021). Treatment of HT29 human colorectal cancer cell line with nanocarrier-encapsulated camptothecin reveals histone modifier genes in the Wnt signaling pathway as important molecular cues for colon cancer targeting. International Journal of Molecular Sciences, 22(22). https://doi.org/10.3390/ijms222212286

309.

Johnston, M. C., Nicoll, J. A., Redmond, K. M., Smyth, P., Greene, M. K., McDaid, W. J., et al. (2020). DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in vivo models. Journal of Controlled Release, 324, 610–619. https://doi.org/10.1016/j.jconrel.2020.05.046CrossRefPubMedPubMedCentral

310.

Rajan, M., Krishnan, P., Pradeepkumar, P., Jeyanthinath, M., Jeyaraj, M., Ling, M. P., et al. (2017). Magneto-chemotherapy for cervical cancer treatment with camptothecin loaded Fe3O4 functionalized beta-cyclodextrin nanovehicle. Rsc Advances, 7(73), 46271–46285. https://doi.org/10.1039/c7ra06615eCrossRef

311.

Sandoval, M. A., Sloat, B. R., Lansakara, D. S. P., Kumar, A., Rodriguez, B. L., Kiguchi, K., et al. (2012). EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity. Journal of Controlled Release, 157(2), 287–296. https://doi.org/10.1016/j.jconrel.2011.08.015CrossRefPubMed

312.

Sundaramoorthy, P., Ramasamy, T., Mishra, S. K., Jeong, K. Y., Yong, C. S., Kim, J. O., et al. (2016). Engineering of caveolae-specific self-micellizing anticancer lipid nanoparticles to enhance the chemotherapeutic efficacy of oxaliplatin in colorectal cancer cells. Acta Biomaterialia, 42, 220–231. https://doi.org/10.1016/j.actbio.2016.07.006CrossRefPubMed

313.

Liu, Y., Qiu, N., Shen, L., Liu, Q., Zhang, J., Cheng, Y. Y., et al. (2020). Nanocarrier-mediated immunogenic chemotherapy for triple negative breast cancer. Journal of Controlled Release, 323, 431–441. https://doi.org/10.1016/j.jconrel.2020.04.040CrossRefPubMedPubMedCentral

314.

Cova, E., Pandolfi, L., Colombo, M., Frangipane, V., Inghilleri, S., Morosini, M., et al. (2019). Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: An in vitro study. International Journal of Nanomedicine, 14, 773–785. https://doi.org/10.2147/ijn.S186344CrossRefPubMedPubMedCentral

315.

Wang, Q., Liu, F. C., Wang, L. F., Xie, C., Wu, P. Y., Du, S. Y., et al. (2020). Enhanced and prolonged antitumor effect of salinomycin-loaded gelatinase-responsive nanoparticles via targeted drug delivery and inhibition of cervical cancer stem cells. International Journal of Nanomedicine, 15, 1283–1295. https://doi.org/10.2147/ijn.S234679CrossRefPubMedPubMedCentral

316.

Lu, Y., Wen, Q., Luo, J., Xiong, K., Wu, Z. X., Wang, B. Q., et al. (2020). Self-assembled dihydroartemisinin nanoparticles as a platform for cervical cancer chemotherapy. Drug Delivery, 27(1), 876–887. https://doi.org/10.1080/10717544.2020.1775725CrossRefPubMedPubMedCentral

317.

Jannu, A. K., Puppala, E. R., Gawali, B., Syamprasad, N. P., Alexander, A., Marepally, S., et al. (2021). Lithocholic acid-tryptophan conjugate (UniPR126) based mixed micelle as a nano carrier for specific delivery of niclosamide to prostate cancer via EphA2 receptor. International Journal of Pharmaceutics, 605, 120819. https://doi.org/10.1016/j.ijpharm.2021.120819CrossRefPubMed

318.

AbouAitah, K., Hassan, H. A., Swiderska-Sroda, A., Gohar, L., Shaker, O. G., Wojnarowicz, J., et al. (2020). Targeted nano-drug delivery of colchicine against colon cancer cells by means of mesoporous silica nanoparticles. Cancers, 12(1). https://doi.org/10.3390/cancers12010144

319.

Kooshki, L., Mahdavi, P., Fakhri, S., Akkol, E. K. & Khan, H. (2022). Targeting lactate metabolism and glycolytic pathways in the tumor microenvironment by natural products: A promising strategy in combating cancer. Biofactors, 48(2), 359–383.

320.

Zhu, L., & Chen, L. (2019). Progress in research on paclitaxel and tumor immunotherapy. Cellular & Molecular Biology Letters, 24(1), 1–11. https://doi.org/10.1186/s11658-019-0164-yCrossRef

321.

Ghosh, S. (2019). Cisplatin: The first metal based anticancer drug. Bioorganic Chemistry, 88, 102925. https://doi.org/10.1016/j.bioorg.2019.102925CrossRefPubMed

322.

Li, F., Jiang, T., Li, Q., & Ling, X. (2017). Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: Did we miss something in CPT analogue molecular targets for treating human disease such as cancer? American Journal of Cancer Research, 7(12), 2350–2394.

323.

Zahavi, D., & Weiner, L. (2020). Monoclonal antibodies in cancer therapy. Antibodies, 9(3), 34. https://doi.org/10.3390/antib9030034CrossRefPubMedPubMedCentral

324.

Baiao, A., Sousa, F., Oliveira, A. V., Oliveira, C., & Sarmento, B. (2020). Effective intracellular delivery of bevacizumab via PEGylated polymeric nanoparticles targeting the CD44v6 receptor in colon cancer cells. Biomaterials Science, 8(13), 3720–3729. https://doi.org/10.1039/d0bm00556hCrossRefPubMed

325.

Kim, M. G., Jo, S. D., Yhee, J. Y., Lee, B. S., Lee, S. J., Park, S. G., et al. (2017). Synergistic anti-tumor effects of bevacizumab and tumor targeted polymerized VEGF siRNA nanoparticles. Biochemical and Biophysical Research Communications, 489(1), 35–41. https://doi.org/10.1016/j.bbrc.2017.05.103CrossRefPubMed

326.

Abedin, M. R., Powers, K., Aiardo, R., Barua, D., & Barua, S. (2021). Antibody-drug nanoparticle induces synergistic treatment efficacies in HER2 positive breast cancer cells. Scientific Reports, 11(1). https://doi.org/10.1038/s41598-021-86762-6

327.

Yan, Y., Cheng, X., Li, L., Zhang, R. M., Zhu, Y., Wu, Z. S., et al. (2021). A novel small molecular antibody, HER2-nanobody, inhibits tumor proliferation in HER2-positive breast cancer cells in vitro and in vivo. Frontiers in Oncology, 11. https://doi.org/10.3389/fonc.2021.669393

328.

Liang, S. J., Sun, M. L., Lu, Y. L., Shi, S., Yang, Y. T., Lin, Y., et al. (2020). Cytokine-induced killer cells-assisted tumor-targeting delivery of Her-2 monoclonal antibody-conjugated gold nanostars with NIR photosensitizer for enhanced therapy of cancer. Journal of Materials Chemistry B, 8(36), 8368–8382. https://doi.org/10.1039/d0tb01391aCrossRefPubMed

329.

Kaluzova, M., Bouras, A., Machaidze, R., & Hadjipanayis, C. G. (2015). Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles. Oncotarget, 6(11), 8788–8806. https://doi.org/10.18632/oncotarget.3554CrossRefPubMedPubMedCentral

330.

Song, L. N., Zhang, W., Chen, H., Zhang, X. Z., Wu, H. A., Ma, M., et al. (2019). Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression. International Journal of Nanomedicine, 14, 921–936. https://doi.org/10.2147/ijn.S185458CrossRefPubMedPubMedCentral

331.

Yu, H. I., Shen, H. C., Chen, S. H., Lim, Y. P., Chuang, H. H., Tai, T. S., et al. (2019). Autophagy modulation in human thyroid cancer cells following aloperine treatment. International Journal of Molecular Sciences, 20(21). https://doi.org/10.3390/ijms20215315

332.

Thao, D., Minh, L., Anh, T. T. M., Nga, N. T., Hue, P. T. K., & Kiem, P. V. (2021). The improved anticancer activities of piperine nanoliposome conjugated CD133 monoclonal antibody against NTERA-2 cancer stem cells. Natural Product Communications, 16(2). https://doi.org/10.1177/1934578x21998184

333.

Niu, F., Yan, J., Ma, B. H., Li, S. C., Shao, Y. P., He, P. C., et al. (2018). Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy. Biomaterials, 167, 132–142. https://doi.org/10.1016/j.biomaterials.2018.03.025CrossRefPubMedPubMedCentral

334.

Yang, C. P., He, X. F., Song, L. N., Zhan, X., Zhang, Y., Dou, J., et al. (2014). gamma-Fe2O3 Nanoparticles increase therapeutic efficacy of combination with paclitaxel and anti-ABCG2 monoclonal antibody on multiple myeloma cancer stem cells in mouse model. Journal of Biomedical Nanotechnology, 10(2), 336–344. https://doi.org/10.1166/jbn.2014.1730CrossRefPubMed

335.

Huang, K. H., Liu, J. H., Wang, L. Y., Zhu, Z. H., Chen, Q. K., Min, J., et al. (2007). Study of the anti-tumor effect of anti-vascular endothelial growth factor McAb 5-fluorouracil loaded polylactic acid nanoparticles. Zhonghua Wei Chang Wai Ke Za Zhi = Chinese Journal of Gastrointestinal Surgery, 10(5), 482–485.

336.

Khatibi, A. S., Roodbari, N. H., Majidzade-A, K., Yaghmaei, P., & Farahmand, L. (2019). In vivo tumor-suppressing and anti-angiogenic activities of a recombinant anti-CD3 epsilon nanobody in breast cancer mice model. Immunotherapy, 11(18), 1555–1567. https://doi.org/10.2217/imt-2019-0068CrossRefPubMed

337.

Chen, L., Huang, Y., Yu, X., Lu, J., Jia, W., Song, J., et al. (2021). Corynoxine protects dopaminergic neurons through inducing autophagy and diminishing neuroinflammation in rotenone-induced animal models of Parkinson’s disease. Frontiers in Pharmacology, 12, 642900. https://doi.org/10.3389/fphar.2021.642900CrossRefPubMedPubMedCentral

338.

Liu, T., Tian, J. G., Chen, Z. L., Liang, Y., Liu, J., Liu, S., et al. (2014). Anti-TROP2 conjugated hollow gold nanospheres as a novel nanostructure for targeted photothermal destruction of cervical cancer cells. Nanotechnology, 25(34). https://doi.org/10.1088/0957-4484/25/34/345103

339.

Pan, H., Li, S., Li, M., Tao, Q., Jia, J., Li, W., et al. (2020). Anti-CD19 mAb-conjugated human serum albumin nanoparticles effectively deliver doxorubicin to B-lymphoblastic leukemia cells. Die Pharmazie, 75(7), 318–323. https://doi.org/10.1691/ph.2020.0026CrossRefPubMed

340.

Liang, Y., Liu, J., Liu, T., & Yang, X. S. (2017). Anti-c-Met antibody bioconjugated with hollow gold nanospheres as a novel nanomaterial for targeted radiation ablation of human cervical cancer cell. Oncology Letters, 14(2), 2254–2260. https://doi.org/10.3892/ol.2017.6383CrossRefPubMedPubMedCentral

341.

He, Y. L., Song, W., Lei, J., Li, Z., Cao, J., Huang, S., et al. (2012). Anti-CXCR4 monoclonal antibody conjugated to ultrasmall superparamagnetic iron oxide nanoparticles in an application of MR molecular imaging of pancreatic cancer cell lines. Acta Radiologica, 53(9), 1049–1058. https://doi.org/10.1258/ar.2012.120055CrossRefPubMed

342.

Han, X., Wei, Q., Lv, Y., Weng, L., Huang, H. Y., Wei, Q. Y., et al. (2022). Ginseng-derived nanoparticles potentiate immune checkpoint antibody efficacy by reprogramming the cold tumor microenvironment. Molecular Therapy, 30(1), 327–340. https://doi.org/10.1016/j.ymthe.2021.08.028CrossRefPubMed

343.

Agostinis, P., Berg, K., Cengel, K. A., Foster, T. H., Girotti, A. W., Gollnick, S. O., et al. (2011). Photodynamic therapy of cancer: An update. CA: A Cancer Journal For Clinicians, 61(4), 250–281. https://doi.org/10.3322/caac.20114CrossRefPubMed

344.

Brown, S. B., Brown, E. A., & Walker, I. (2004). The present and future role of photodynamic therapy in cancer treatment. The Lancet Oncology, 5(8), 497–508. https://doi.org/10.1016/S1470-2045(04)01529-3CrossRefPubMed

345.

Shibu, E. S., Hamada, M., Murase, N., & Biju, V. (2013). Nanomaterials formulations for photothermal and photodynamic therapy of cancer. Journal of Photochemistry and Photobiology C: Photochemistry Reviews, 15, 53–72. https://doi.org/10.1016/j.jphotochemrev.2012.09.004CrossRef

346.

Chang, Y. Z., He, L. Z., Li, Z. B., Zeng, L. L., Song, Z. H., Li, P. H., et al. (2017). Designing Core-Shell Gold and Selenium Nanocomposites for Cancer Radiochemotherapy. ACS Nano, 11(5), 4848–4858. https://doi.org/10.1021/acsnano.7b01346CrossRefPubMed

347.

Zhang, X. D., Wu, D., Shen, X., Chen, J., Sun, Y. M., Liu, P. X., et al. (2012). Size-dependent radiosensitization of PEG-coated gold nanoparticles for cancer radiation therapy. Biomaterials, 33(27), 6408–6419. https://doi.org/10.1016/j.biomaterials.2012.05.047CrossRefPubMed

348.

Yasui, H., Takeuchi, R., Nagane, M., Meike, S., Nakamura, Y., Yamamori, T., et al. (2014). Radiosensitization of tumor cells through endoplasmic reticulum stress induced by PEGylated nanogel containing gold nanoparticles. Cancer Letters, 347(1), 151–158. https://doi.org/10.1016/j.canlet.2014.02.005CrossRefPubMed

349.

Darwesh, R., Aboushoushah, S. F., Almarhabi, S., Aldahlawi, A. M., & Elbialy, N. S. (2021). TurboBeads magnetic nanoparticles functionalized with gold as a promising nano-radiosensitizer for potential breast cancer radiotherapy: In vitro study. Inorganic Chemistry Communications, 123. https://doi.org/10.1016/j.inoche.2020.108348

350.

Wang, X. H., Niu, X. Y., Sha, W. Z., Feng, X. Y., Yu, L. C., Zhang, Z. J., et al. (2021). An oxidation responsive nano-radiosensitizer increases radiotherapy efficacy by remolding tumor vasculature. Biomaterials Science, 9(18), 6308–6324. https://doi.org/10.1039/d1bm00834jCrossRefPubMed

351.

Alamzadeh, Z., Beik, J., Mirrahimi, M., Shakeri-Zadeh, A., Ebrahimi, F., Komeili, A., et al. (2020). Gold nanoparticles promote a multimodal synergistic cancer therapy strategy by co-delivery of thermo-chemo-radio therapy. European Journal of Pharmaceutical Sciences, 145. https://doi.org/10.1016/j.ejps.2020.105235

352.

Popovtzer, A., Mizrachi, A., Motiei, M., Bragilovski, D., Lubimov, L., Levi, M., et al. (2016). Actively targeted gold nanoparticles as novel radiosensitizer agents: An in vivo head and neck cancer model. Nanoscale, 8(5), 2678–2685. https://doi.org/10.1039/c5nr07496gCrossRefPubMed

353.

Banu, H., Sethi, D. K., Edgar, A., Sheriff, A., Rayees, N., Renuka, N., et al. (2015). Doxorubicin loaded polymeric gold nanoparticles targeted to human folate receptor upon laser photothermal therapy potentiates chemotherapy in breast cancer cell lines. Journal of Photochemistry and Photobiology B-Biology, 149, 116–128. https://doi.org/10.1016/j.jphotobiol.2015.05.008CrossRefPubMed

354.

Liu, J. Y., Ma, W., Kou, W., Shang, L. N., Huang, R., & Zhao, J. (2019). Poly-amino acids coated gold nanorod and doxorubicin for synergistic photodynamic therapy and chemotherapy in ovarian cancer cells. Bioscience Reports, 39. https://doi.org/10.1042/bsr2019252

355.

Zhao, N., Yang, Z. R., Li, B. X., Meng, J., Shi, Z. L., Li, P., et al. (2016). RGD-conjugated mesoporous silica-encapsulated gold nanorods enhance the sensitization of triple-negative breast cancer to megavoltage radiation therapy. International Journal of Nanomedicine, 11, 5595–5610. https://doi.org/10.2147/ijn.S104034CrossRefPubMedPubMedCentral

356.

Xu, W., Luo, T., Li, P., Zhou, C., Cui, D., Pang, B., et al. (2012). RGD-conjugated gold nanorods induce radiosensitization in melanoma cancer cells by downregulating α(v)β₃ expression. International Journal of Nanomedicine, 7, 915–924. https://doi.org/10.2147/ijn.S28314CrossRefPubMedPubMedCentral

357.

Vilchis-Juarez, A., Ferro-Flores, G., Santos-Cuevas, C., Morales-Avila, E., Ocampo-Garcia, B., Diaz-Nieto, L., et al. (2014). Molecular targeting radiotherapy with cyclo-RGDfK(C) peptides conjugated to Lu-177-labeled gold nanoparticles in tumor-bearing mice. Journal of Biomedical Nanotechnology, 10(3), 393–404. https://doi.org/10.1166/jbn.2014.1721CrossRefPubMed

358.

Ding, Y., Sun, Z. Q., Tong, Z. R., Zhang, S. T., Min, J., Xu, Q. H., et al. (2020). Tumor microenvironment-responsive multifunctional peptide coated ultrasmall gold nanoparticles and their application in cancer radiotherapy. Theranostics, 10(12), 5195–5208. https://doi.org/10.7150/thno.45017CrossRefPubMedPubMedCentral

359.

Zhang, X. Y., Wang, H., Coulter, J. A., & Yang, R. J. (2018). Octaarginine-modified gold nanoparticles enhance the radiosensitivity of human colorectal cancer cell line LS180 to megavoltage radiation. International Journal of Nanomedicine, 13, 3541–3552. https://doi.org/10.2147/ijn.S161157CrossRefPubMedPubMedCentral

360.

Liu, S., Li, H., Xia, L. Y., Xu, P. P., Ding, Y., Huo, D., et al. (2017). Anti-RhoJ antibody functionalized Au@I nanoparticles as CT-guided tumor vessel-targeting radiosensitizers in patient-derived tumor xenograft model. Biomaterials, 141, 1–12. https://doi.org/10.1016/j.biomaterials.2017.06.036CrossRefPubMed

361.

Liu, J., Liang, Y., Liu, T., Li, D. K., & Yang, X. S. (2015). Anti-EGFR-conjugated hollow gold nanospheres enhance radiocytotoxic targeting of cervical cancer at megavoltage radiation energies. Nanoscale Research Letters, 10. https://doi.org/10.1186/s11671-015-0923-2

362.

Wang, C. H., Li, X. H., Wang, Y., Liu, Z., Fu, L., & Hu, L. K. (2013). Enhancement of radiation effect and increase of apoptosis in lung cancer cellsS by thio-glucose-bound gold nanoparticles at megavoltage radiation energies. Journal of Nanoparticle Research, 15(5). https://doi.org/10.1007/s11051-013-1642-1

363.

Geng, F., Song, K., Xing, J. Z., Yuan, C. Z., Yan, S., Yang, Q. F., et al. (2011). Thio-glucose bound gold nanoparticles enhance radio-cytotoxic targeting of ovarian cancer. Nanotechnology, 22(28). https://doi.org/10.1088/0957-4484/22/28/285101

364.

Liu, T., Shi, C. Z., Duan, L. Q., Zhang, Z. H., Luo, L. P., Goel, S., et al. (2018). A highly hemocompatible erythrocyte membrane-coated ultrasmall selenium nanosystem for simultaneous cancer radiosensitization and precise antiangiogenesis. Journal of Materials Chemistry B, 6(29), 4756–4764. https://doi.org/10.1039/c8tb01398eCrossRefPubMedPubMedCentral

365.

Tian, J. X., Weil, X. Y., Zhang, W. H., & Xu, A. G. (2020). Effects of selenium nanoparticles combined with radiotherapy on lung cancer cells. Frontiers in Bioengineering and Biotechnology, 8. https://doi.org/10.3389/fbioe.2020.598997

366.

Chan, L., He, L., Zhou, B., Guan, S., Bo, M., Yang, Y., et al. (2017). Cancer-targeted selenium nanoparticles sensitize cancer cells to continuous γ radiation to achieve synergetic chemo-radiotherapy. Chemistry - An Asian Journal, 12(23), 3053–3060. https://doi.org/10.1002/asia.201701227CrossRefPubMed

367.

Yang, Y. H., Xie, Q., Zhao, Z. N., He, L. Z., Chan, L., Liu, Y. X., et al. (2017). Functionalized selenium nanosystem as radiation sensitizer of I-125 seeds for precise cancer therapy. ACS Applied Materials & Interfaces, 9(31), 25857–25869. https://doi.org/10.1021/acsami.7b07167CrossRef

368.

Chen, F., Zhang, X. H., Hu, X. D., Liu, P. D., & Zhang, H. Q. (2018). The effects of combined selenium nanoparticles and radiation therapy on breast cancer cells in vitro. Artificial Cells Nanomedicine and Biotechnology, 46(5), 937–948. https://doi.org/10.1080/21691401.2017.1347941CrossRefPubMed

369.

Abozaid, O. A. R., Rashed, L. A., El-Sonbaty, S. M., Abu-Elftouh, A. I., & Ahmed, E. S. A. Mesenchymal stem cells and selenium nanoparticles synergize with low dose of gamma radiation to suppress mammary gland carcinogenesis via regulation of tumor microenvironment. Biological Trace Element Research. https://doi.org/10.1007/s12011-022-03146-1

370.

Zangeneh, M., Nedaei, H. A., Mozdarani, H., Mahmoudzadeh, A., & Salimi, M. (2019). Enhanced cytotoxic and genotoxic effects of gadolinium-doped ZnO nanoparticles on irradiated lung cancer cells at megavoltage radiation energies. Materials Science & Engineering C-Materials for Biological Applications, 103. https://doi.org/10.1016/j.msec.2019.109739

371.

Arab-Bafrani, Z., Zabihi, E., Jafari, S. M., Khoshbin-Khoshnazar, A., Mousavi, E., Khalili, M., et al. (2021). Enhanced radiotherapy efficacy of breast cancer multi cellular tumor spheroids through in-situ fabricated chitosan-zinc oxide bio-nanocomposites as radio-sensitizing agents. International Journal of Pharmaceutics, 605. https://doi.org/10.1016/j.ijpharm.2021.120828

372.

Ghaleh, H. E. G., Zarei, L., Motlagh, B. M., & Jabbari, N. (2019). Using CuO nanoparticles and hyperthermia in radiotherapy of MCF-7 cell line: Synergistic effect in cancer therapy. Artificial Cells Nanomedicine and Biotechnology, 47(1), 1396–1403. https://doi.org/10.1080/21691401.2019.1600529CrossRef

373.

Yi, X., Chen, L., Chen, J., Maiti, D., Chai, Z. F., Liu, Z., et al. (2018). Biomimetic copper sulfide for chemo-radiotherapy: Enhanced uptake and reduced efflux of nanoparticles for tumor cells under ionizing radiation. Advanced Functional Materials, 28(9). https://doi.org/10.1002/adfm.201705161

374.

Fan, Y., Zhang, J. L., Shi, M. H., Li, D., Lu, C. H., Cao, X. Y., et al. (2019). Poly(amidoamine) Dendrimer-coordinated copper(II) complexes as a theranostic nanoplatform for the radiotherapy-enhanced magnetic resonance imaging and chemotherapy of tumors and tumor metastasis. Nano Letters, 19(2), 1216–1226. https://doi.org/10.1021/acs.nanolett.8b04757CrossRefPubMed

375.

Movahedi, M. M., Alamzadeh, Z., Hosseini-Nami, S., Shakeri-Zadeh, A., Taheripak, G., Ahmadi, A., et al. (2020). Investigating the mechanisms behind extensive death in human cancer cells following nanoparticle assisted photo-thermo-radiotherapy. Photodiagnosis and Photodynamic Therapy, 29. https://doi.org/10.1016/j.pdpdt.2019.101600

376.

Duval, K. E. A., Vernice, N. A., Wagner, R. J., Fiering, S. N., Petryk, J. D., Lowry, G. J., et al. (2019). Immunogenetic effects of low dose (CEM43 30) magnetic nanoparticle hyperthermia and radiation in melanoma cells. International Journal of Hyperthermia, 36, 37–46. https://doi.org/10.1080/02656736.2019.1627433CrossRefPubMedPubMedCentral

377.

Hadi, F., Tavakkol, S., Laurent, S., Pirhajati, V., Mahdavi, S. R., Neshastehriz, A., et al. (2019). Combinatorial effects of radiofrequency hyperthermia and radiotherapy in the presence of magneto-plasmonic nanoparticles on MCF-7 breast cancer cells. Journal of Cellular Physiology, 234(11), 20028–20035. https://doi.org/10.1002/jcp.28599CrossRefPubMed

378.

Li, Y., Yang, J., Gu, G., Guo, X., He, C., Sun, J., et al. (2022). Pulmonary delivery of theranostic nanoclusters for lung cancer ferroptosis with enhanced chemodynamic/radiation synergistic therapy. Nano Letters, 22(3), 963–972. https://doi.org/10.1021/acs.nanolett.1c03786CrossRefPubMed

379.

Ma, J., Zhang, Z. P., Zhang, Z. J., Huang, J., Qin, Y., Li, X., et al. (2015). Magnetic nanoparticle clusters radiosensitise human nasopharyngeal and lung cancer cells after alternating magnetic field treatment. International Journal of Hyperthermia, 31(7), 800–812. https://doi.org/10.3109/02656736.2015.1063168CrossRefPubMed

380.

Salem, M. L., Gemeay, A., Gomaa, S., Aldubayan, M. A., & Assy, L. (2020). Superparamagnetic graphene oxide/magnetite nanocomposite delivery system for doxorubicin-induced distinguished tumor cell cycle arrest and apoptosis. Journal of Nanoparticle Research, 22(8). https://doi.org/10.1007/s11051-020-04932-5

381.

Shetake, N. G., Kumar, A., & Pandey, B. N. (2019). Iron-oxide nanoparticles target intracellular HSP90 to induce tumor radio-sensitization. Biochimica Et Biophysica Acta-General Subjects, 1863(5), 857–869. https://doi.org/10.1016/j.bbagen.2019.02.010CrossRefPubMed

382.

Wason, M. S., Lu, H., Yu, L., Lahiri, S. K., Mukherjee, D., Shen, C., et al. (2018). Cerium oxide nanoparticles sensitize pancreatic cancer to radiation therapy through oxidative activation of the JNK apoptotic pathway. Cancers, 10(9). https://doi.org/10.3390/cancers10090303

383.

Wason, M. S., Colon, J., Das, S., Seal, S., Turkson, J., Zhao, J. H., et al. (2013). Sensitization of pancreatic cancer cells to radiation by cerium oxide nanoparticle-induced ROS production. Nanomedicine-Nanotechnology Biology and Medicine, 9(4), 558–569. https://doi.org/10.1016/j.nano.2012.10.010CrossRefPubMed

384.

Chen, F., Zhang, X. H., Hu, X. D., Zhang, W., Lou, Z. C., Xie, L. H., et al. (2015). Enhancement of radiotherapy by ceria nanoparticles modified with neogambogic acid in breast cancer cells. International Journal of Nanomedicine, 10, 4957–4969. https://doi.org/10.2147/ijn.S82980CrossRefPubMedPubMedCentral

385.

Azizi, S., Ghasemi, A., Asgarian-Omran, H., Zal, Z., Montazeri, A., Yazdannejat, H., et al. (2018). Cerium oxide nanoparticles sensitize non-small lung cancer cell to ionizing radiation. Marmara Pharmaceutical Journal, 22(2), 307–313. https://doi.org/10.12991/mpj.2018.68CrossRef

386.

Li, F. F., Li, Z. H., Jin, X. D., Liu, Y., Zhang, P. C., Li, P., et al. (2019). Ultra-small gadolinium oxide nanocrystal sensitization of non-small-cell lung cancer cells toward X-ray irradiation by promoting cytostatic autophagy. International Journal of Nanomedicine, 14, 2415–2431. https://doi.org/10.2147/ijn.S193676CrossRefPubMedPubMedCentral

387.

Tamborini, M., Locatelli, E., Rasile, M., Monaco, I., Rodighiero, S., Corradini, I., et al. (2016). A combined approach employing chlorotoxin-nanovectors and low dose radiation to reach infiltrating tumor niches in glioblastoma. ACS Nano, 10(2), 2509–2520. https://doi.org/10.1021/acsnano.5b07375CrossRefPubMed

388.

Shin, S. W., Yang, K., Lee, M., Moon, J., Son, A., Kim, Y., et al. (2021). Manganese ferrite nanoparticles enhance the sensitivity of Hepa1–6 hepatocellular carcinoma to radiation by remodeling tumor microenvironments. International Journal of Molecular Sciences, 22(5). https://doi.org/10.3390/ijms22052637

389.

Abbasi, A. Z., Gordijo, C. R., Amini, M. A., Maeda, A., Rauth, A. M., DaCosta, R. S., et al. (2016). Hybrid manganese dioxide nanoparticles potentiate radiation therapy by modulating tumor hypoxia. Cancer Research, 76(22), 6643–6656. https://doi.org/10.1158/0008-5472.Can-15-3475CrossRefPubMed

390.

Prasad, P., Gordijo, C. R., Abbasi, A. Z., Maeda, A., Ip, A., Rauth, A. M., et al. (2014). Multifunctional albumin-MnO2 nanoparticles modulate solid tumor microenvironment by attenuating hypoxia, acidosis, vascular endothelial growth factor and enhance radiation response. ACS Nano, 8(4), 3202–3212. https://doi.org/10.1021/nn405773rCrossRefPubMed

391.

Zhu, C., Ma, Q., Gong, L., Di, S., Gong, J., Wang, Y., et al. (2022). Manganese-based multifunctional nanoplatform for dual-modal imaging and synergistic therapy of breast cancer. [Article]. Acta Biomaterialia. https://doi.org/10.1016/j.actbio.2022.01.019

392.

Jia, Y. J., Weng, Z. Y., Wang, C. Y., Zhu, M. J., Lu, Y. S., Ding, L. L., et al. (2017). Increased chemosensitivity and radiosensitivity of human breast cancer cell lines treated with novel functionalized single-walled carbon nanotubes. Oncology Letters, 13(1), 206–214. https://doi.org/10.3892/ol.2016.5402CrossRefPubMed

393.

Askar, M. A., Thabet, N. M., El-Sayyad, G. S., El-Batal, A. I., Abd Elkodous, M., El Shawi, O. E., et al. (2021). Dual hyaluronic acid and folic acid targeting pH-sensitive multifunctional 2DG@DCA@MgO-nano-core-shell-radiosensitizer for breast cancer therapy. Cancers, 13(21). https://doi.org/10.3390/cancers13215571

394.

Shirvalilou, S., Khoei, S., Khoee, S., Mahdavi, S. R., Raoufi, N. J., Motevalian, M., et al. (2020). Enhancement radiation-induced apoptosis in C6 glioma tumor-bearing rats via pH-responsive magnetic graphene oxide nanocarrier. Journal of Photochemistry and Photobiology B-Biology, 205. https://doi.org/10.1016/j.jphotobiol.2020.111827

395.

Peng, X., Yang, C., Kong, X., Xiang, Y., Dai, W., & Quan, H. (2020). Multifunctional nanocomposites MGO/FU-MI inhibit the proliferation of tumor cells and enhance the effect of chemoradiotherapy in vivo and in vitro. Clinical & Translational Oncology, 22(10), 1875–1884. https://doi.org/10.1007/s12094-020-02331-9CrossRef

396.

Liu, R. X., Gong, L. J., Zhu, X. Y., Zhu, S., Wu, X. C., Xue, T. Y., et al. Transformable gallium-based liquid metal nanoparticles for tumor radiotherapy sensitization. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202102584

397.

Dou, Y., Zhao, F. S., Li, X., & Guo, Y. Y. (2021). Monitoring nitric oxide-induced hypoxic tumor radiosensitization by radiation-activated nanoagents under BOLD/DWI imaging. ACS Biomaterials Science & Engineering, 7(11), 5242–5254. https://doi.org/10.1021/acsbiomaterials.1c00543CrossRef

398.

Li, S. Y., Sun, W. J., Luo, Y., Gao, Y. P., Jiang, X. P., Yuan, C., et al. (2021). Hollow PtCo alloy nanospheres as a high-Z and oxygen generating nanozyme for radiotherapy enhancement in non-small cell lung cancer. Journal of Materials Chemistry B, 9(23), 4643–4653. https://doi.org/10.1039/d1tb00486gCrossRefPubMed

399.

Sun, M. D., Zhang, Y., He, Y., Xiong, M. H., Huang, H. Y., Pei, S. C., et al. (2019). Green synthesis of carrier-free curcumin nanodrugs for light-activated breast cancer photodynamic therapy. Colloids and Surfaces B-Biointerfaces, 180, 313–318. https://doi.org/10.1016/j.colsurfb.2019.04.061CrossRefPubMed

400.

Khorsandi, K., Hosseinzadeh, R., & Shahidi, F. K. (2019). Photodynamic treatment with anionic nanoclays containing curcumin on human triple-negative breast cancer cells: Cellular and biochemical studies. Journal of Cellular Biochemistry, 120(4), 4998–5009. https://doi.org/10.1002/jcb.27775CrossRefPubMed

401.

Askar, M. A., El Shawi, O. E., Abou Zaid, O. A. R., Mansour, N. A., & Hanafy, A. M. (2021). Breast cancer suppression by curcumin-naringenin-magnetic-nano-particles: In vitro and in vivo studies. Tumour Biology, 43(1), 225–247. https://doi.org/10.3233/tub-211506CrossRefPubMed

402.

Castro, F., Pinto, M. L., Pereira, C. L., Serre, K., Barbosa, M. A., Vermaelen, K., et al. (2020). Chitosan/gamma-PGA nanoparticles-based immunotherapy as adjuvant to radiotherapy in breast cancer. Biomaterials, 257. https://doi.org/10.1016/j.biomaterials.2020.120218

403.

Yu, Y. X., Xu, S., You, H., Zhang, Y. J., Yang, B., Sun, X. Y., et al. (2017). In vivo synergistic anti-tumor effect of paclitaxel nanoparticles combined with radiotherapy on human cervical carcinoma. Drug Delivery, 24(1), 75–82. https://doi.org/10.1080/10717544.2016.1230902CrossRefPubMedPubMedCentral

404.

Bhardwaj, P., Gota, V., Vishwakarma, K., Pai, V., Chaudhari, P., Mohanty, B., et al. (2022). Loco-regional radiosensitizing nanoparticles-in-gel augments head and neck cancer chemoradiotherapy. Journal of Controlled Release, 343, 288–302. https://doi.org/10.1016/j.jconrel.2022.01.040CrossRefPubMed

405.

He, Z., Jiang, H., Zhang, X., Zhang, H., Cui, Z., Sun, L., et al. (2020). Nano-delivery vehicle based on chlorin E6, photodynamic therapy, doxorubicin chemotherapy provides targeted treatment of HER-2 negative, ανβ3-positive breast cancer. Pharmacological Research, 160, 105184. https://doi.org/10.1016/j.phrs.2020.105184CrossRefPubMed

406.

Zhang, T., Liu, H., Li, L., Guo, Z. Y., Song, J., Yang, X. Y., et al. (2021). Leukocyte/platelet hybrid membrane-camouflaged dendritic large pore mesoporous silica nanoparticles co-loaded with photo/chemotherapeutic agents for triple negative breast cancer combination treatment. Bioactive Materials, 6(11), 3865–3878. https://doi.org/10.1016/j.bioactmat.2021.04.004CrossRefPubMedPubMedCentral

407.

Park, J., Park, S. S., Lee, K. J., Ju, E. J., Shin, S. H., Ko, E. J., et al. (2018). Docetaxel-polymeric nanoparticle enhances radiotherapeutic efficacy in human pancreatic cancer. Translational Cancer Research, 7(1), 60–67. https://doi.org/10.21037/tcr.2018.01.09CrossRef

408.

Jiang, D., Xu, M. J., Pei, Y. Y., Huang, Y. K., Chen, Y., Ma, F. F., et al. (2019). Core-matched nanoassemblies for targeted co-delivery of chemotherapy and photosensitizer to treat drug-resistant cancer. Acta Biomaterialia, 88, 406–421. https://doi.org/10.1016/j.actbio.2019.02.009CrossRefPubMed

409.

Yang, H. L., Zhao, P., Zhou, Y. G., Li, Q. Y., Cai, W. B., Zhao, Z. X., et al. (2021). Preparation of multifunctional nanobubbles and their application in bimodal imaging and targeted combination therapy of early pancreatic cancer. Scientific Reports, 11(1). https://doi.org/10.1038/s41598-021-82602-9

410.

Au, K. M., Min, Y. Z., Tian, X., Zhang, L. Z., Perello, V., Caster, J. M., et al. (2015). Improving cancer chemoradiotherapy treatment by dual controlled release of wortmannin and docetaxel in polymeric nanoparticles. ACS Nano, 9(9), 8976–8996. https://doi.org/10.1021/acsnano.5b02913CrossRefPubMedPubMedCentral

411.

Liang, B. J., Pigula, M., Baglo, Y., Najafali, D. A., Hasan, T., & Huang, H. C. (2020). Breaking the selectivity-uptake trade-off of photoimmunoconjugates with nanoliposomal irinotecan for synergistic multi-tier cancer targeting. Journal of Nanobiotechnology, 18(1). https://doi.org/10.1186/s12951-019-0560-5

412.

Gangopadhyay, M., Mukhopadhyay, S. K., Karthik, S., Barman, S., & Singh, N. D. P. (2015). Targeted photoresponsive TiO2-coumarin nanoconjugate for efficient combination therapy in MDA-MB-231 breast cancer cells: Synergic effect of photodynamic therapy (PDT) and anticancer drug chlorambucil. Medchemcomm, 6(5), 769–777. https://doi.org/10.1039/c4md00481gCrossRef

413.

Zong, J. J., Peng, H., Qing, X., Fan, Z., Xu, W. J., Du, X. L., et al. (2021). pH-responsive pluronic F127-lenvatinib-encapsulated halogenated boron-dipyrromethene nanoparticles for combined photodynamic therapy and chemotherapy of liver cancer. ACS Omega, 6(18), 12331–12342. https://doi.org/10.1021/acsomega.1c01346CrossRefPubMedPubMedCentral

414.

Liu, S., Liu, H., Sun, H., Deng, S., Yue, L., Weng, Z., et al. (2022). (cRGD)2 peptides modified nanoparticles increase tumor-targeting therapeutic effects by co-delivery of albendazole and iodine-131. Anti-Cancer Drugs, 33(1), 19–29. https://doi.org/10.1097/cad.0000000000001135CrossRefPubMed

415.

Poudel, K., Banstola, A., Gautam, M., Soe, Z. C., Pham, L. M., Jeong, J. H., et al. (2021). Redox/photo dual-responsive, self-targeted, and photosensitizer-laden bismuth sulfide nanourchins for combination therapy in cancer. Nanoscale, 13(2), 1231–1247. https://doi.org/10.1039/d0nr07736dCrossRefPubMed

416.

Zhang, X. J., Liu, N. L., Shao, Z. Y., Qiu, H., Yao, H., Ji, J. Y., et al. (2017). Folate-targeted nanoparticle delivery of androgen receptor shRNA enhances the sensitivity of hormone-independent prostate cancer to radiotherapy. Nanomedicine-Nanotechnology Biology and Medicine, 13(4), 1309–1321. https://doi.org/10.1016/j.nano.2017.01.015CrossRefPubMed

417.

Villa, I., Villa, C., Crapanzano, R., Secchi, V., Tawfilas, M., Trombetta, E., et al. (2021). Functionalized scintillating nanotubes for simultaneous radio- and photodynamic therapy of cancer. ACS Applied Materials & Interfaces, 13(11), 12997–13008. https://doi.org/10.1021/acsami.1c02504CrossRef

418.

Lan, J. S., Liu, L., Zeng, R. F., Qin, Y. H., Hou, J. W., Xie, S. S., et al. (2021). Tumor-specific carrier-free nanodrugs with GSH depletion and enhanced ROS generation for endogenous synergistic anti-tumor by a chemotherapy-photodynamic therapy. Chemical Engineering Journal, 407. https://doi.org/10.1016/j.cej.2020.127212

419.

Chen, Y. Y., Zhong, H., Wang, J. B., Wan, X. Y., Li, Y. H., Pan, W., et al. (2019). Catalase-like metal-organic framework nanoparticles to enhance radiotherapy in hypoxic cancer and prevent cancer recurrence. Chemical Science, 10(22), 5773–5778. https://doi.org/10.1039/c9sc00747dCrossRefPubMedPubMedCentral

420.

Mehtala, J. G., Torregrosa-Allen, S., Elzey, B. D., Jeon, M., Kim, C., & Wei, A. (2014). Synergistic effects of cisplatin chemotherapy and gold nanorod-mediated hyperthermia on ovarian cancer cells and tumors. Nanomedicine, 9(13), 1939–1955. https://doi.org/10.2217/nnm.13.209CrossRefPubMed

421.

Siahmansouri, H., Somi, M. H., Babaloo, Z., Baradaran, B., Jadidi-Niaragh, F., Atyabi, F., et al. (2016). Effects of HMGA2 siRNA and doxorubicin dual delivery by chitosan nanoparticles on cytotoxicity and gene expression of HT-29 colorectal cancer cell line. Journal of Pharmacy and Pharmacology, 68(9), 1119–1130. https://doi.org/10.1111/jphp.12593CrossRefPubMed

422.

Zheng, X., Zhao, Y. W., Jia, Y., Shao, D., Zhang, F., Sun, M. D., et al. (2021). Biomimetic co-assembled nanodrug of doxorubicin and berberine suppresses chemotherapy-exacerbated breast cancer metastasis. Biomaterials, 271. https://doi.org/10.1016/j.biomaterials.2021.120716

423.

Zhang, H. Y., Yi, Z., Sun, Z., Ma, X. M., & Li, X. D. (2017). Functional nanoparticles of tea polyphenols for doxorubicin delivery in cancer treatment. Journal of Materials Chemistry B, 5(36), 7622–7631. https://doi.org/10.1039/c7tb01323jCrossRefPubMed

424.

Ray, L., Kumar, P., & Gupta, K. C. (2013). The activity against Ehrlich’s ascites tumors of doxorubicin contained in self assembled, cell receptor targeted nanoparticle with simultaneous oral delivery of the green tea polyphenol epigallocatechin-3-gallate. Biomaterials, 34(12), 3064–3076. https://doi.org/10.1016/j.biomaterials.2012.12.044CrossRefPubMed

425.

Mahjoub, M. A., Bakhshinejad, B., Sadeghizadeh, M., & Babashah, S. (2017). Combination treatment with dendrosomal nanocurcumin and doxorubicin improves anticancer effects on breast cancer cells through modulating CXCR4/NF-κB/Smo regulatory network. Molecular Biology Reports, 44(4), 341–351. https://doi.org/10.1007/s11033-017-4115-2CrossRefPubMed

426.

Yaghoubi, F., Naghib, S. M., Motlagh, N. S. H., Haghiralsadat, F., Jaliani, H. Z., Tofighi, D., et al. (2021). Multiresponsive carboxylated graphene oxide-grafted aptamer as a multifunctional nanocarrier for targeted delivery of chemotherapeutics and bioactive compounds in cancer therapy. Nanotechnology Reviews, 10(1), 1838–1852. https://doi.org/10.1515/ntrev-2021-0110CrossRef

427.

Li, M. X., Liu, P., Gao, G. H., Deng, J. Z., Pan, Z. Y., Wu, X., et al. (2015). Smac therapeutic peptide nanoparticles inducing apoptosis of cancer cells for combination chemotherapy with doxorubicin. ACS Applied Materials & Interfaces, 7(15), 8005–8012. https://doi.org/10.1021/acsami.5b00329CrossRef

428.

Nejabat, M., Eisvand, F., Soltani, F., Alibolandi, M., Taghdisi, S. M., Abnous, K., et al. (2020). Combination therapy using Smac peptide and doxorubicin-encapsulated MUC 1-targeted polymeric nanoparticles to sensitize cancer cells to chemotherapy: An in vitro and in vivo study. International Journal of Pharmaceutics, 587. https://doi.org/10.1016/j.ijpharm.2020.119650

429.

Astani, S., Salehi, R., Massoumi, B., & Massoudi, A. (2021). Co-delivery of cisplatin and doxorubicin by carboxylic acid functionalized poly (hydroxyethyl methacrylate)/reduced graphene nanocomposite for combination chemotherapy of breast cancer cells. Journal of Biomaterials Science-Polymer Edition, 32(5), 657–677. https://doi.org/10.1080/09205063.2020.1855393CrossRefPubMed

430.

Wang, R. N., Yang, Y. J., Yang, M. M., Yuan, D. D., Huang, J. Y., Chen, R., et al. (2020). Synergistic inhibition of metastatic breast cancer by dual-chemotherapy with excipient-free rhein/DOX nanodispersions. Journal of Nanobiotechnology, 18(1). https://doi.org/10.1186/s12951-020-00679-2

431.

Sun, P. C., Zhang, N., Tang, Y. F., Yang, Y. N., Chu, X., & Zhao, Y. X. (2017). SL2B aptamer and folic acid dual-targeting DNA nanostructures for synergic biological effect with chemotherapy to combat colorectal cancer. International Journal of Nanomedicine, 12, 2657–2672. https://doi.org/10.2147/ijn.S132929CrossRefPubMedPubMedCentral

432.

Li, J. X., Zhang, L. M., Liu, C. C., Wu, Q. N., Li, S. P., Lei, X. P., et al. (2021). Doxorubicin-loaded hydrogen peroxide self-providing copper nanodots for combination of chemotherapy and acid-induced chemodynamic therapy against breast cancer. Journal of Colloid and Interface Science, 593, 323–334. https://doi.org/10.1016/j.jcis.2021.02.085CrossRefPubMed

433.

Krishnan, V., Dharamdasani, V., Bakre, S., Dhole, V., Wu, D. B., Budnik, B., et al. (2022). Hyaluronic acid nanoparticles for immunogenic chemotherapy of leukemia and T-cell lymphoma. Pharmaceutics, 14(2). https://doi.org/10.3390/pharmaceutics14020466

434.

Liu, J., Zheng, J. X., Nie, H. F., Chen, H. N., Li, B. F., & Jia, L. (2020). Co-delivery of erlotinib and doxorubicin by MoS2 nanosheets for synergetic photothermal chemotherapy of cancer.Chemical Engineering Journal, 381. https://doi.org/10.1016/j.cej.2019.122541

435.

Lee, K. W., Jeong, D., & Na, K. (2013). Doxorubicin loading fucoidan acetate nanoparticles for immune and chemotherapy in cancer treatment. Carbohydrate Polymers, 94(2), 850–856. https://doi.org/10.1016/j.carbpol.2013.02.018CrossRefPubMed

436.

Zou, L., Liu, X. W., Li, J. J., Li, W., Zhang, L. L., Fu, C. M., et al. (2021). Redox-sensitive carrier-free nanoparticles self-assembled by disulfide-linked paclitaxel-tetramethylpyrazine conjugate for combination cancer chemotherapy. Theranostics, 11(9), 4171–4186. https://doi.org/10.7150/thno.42260CrossRefPubMedPubMedCentral

437.

Zhang, C., Zhao, Y., Zhang, E., Jiang, M., Zhi, D., Chen, H., et al. (2020). Co-delivery of paclitaxel and anti-VEGF siRNA by tripeptide lipid nanoparticle to enhance the anti-tumor activity for lung cancer therapy. Drug Delivery, 27(1), 1397–1411. https://doi.org/10.1080/10717544.2020.1827085CrossRefPubMedPubMedCentral

438.

Huo, M. R., Wang, H. L., Zhang, Y., Cai, H., Zhang, P., Li, L. C., et al. (2020). Co-delivery of silybin and paclitaxel by dextran-based nanoparticles for effective anti-tumor treatment through chemotherapy sensitization and microenvironment modulation. Journal of Controlled Release, 321, 198–210. https://doi.org/10.1016/j.jconrel.2020.02.017CrossRefPubMed

439.

Hariri, G., Edwards, A. D., Merrill, T. B., Greenbaum, J. M., van der Ende, A. E., & Harth, E. (2014). Sequential targeted delivery of paclitaxel and camptothecin using a cross-linked “nanosponge” network for lung cancer chemotherapy. Molecular Pharmaceutics, 11(1), 265–275. https://doi.org/10.1021/mp400432bCrossRefPubMed

440.

Pal, M. K., Jaiswar, S. P., Dwivedi, A., Goyal, S., Dwivedi, V. N., Pathak, A. K., et al. (2017). Synergistic effect of graphene oxide coated nanotised apigenin with paclitaxel (GO-NA/PTX): A ROS dependent mitochondrial mediated apoptosis in ovarian cancer. Anti-Cancer Agents in Medicinal Chemistry, 17(12), 1721–1732. https://doi.org/10.2174/1871520617666170425094549CrossRefPubMed

441.

Lin, Y. W., Raj, E. N., Liao, W. S., Lin, J., Liu, K. K., Chen, T. H., et al. (2017). Co-delivery of paclitaxel and cetuximab by nanodiamond enhances mitotic catastrophe and tumor inhibition. Scientific Reports, 7. https://doi.org/10.1038/s41598-017-09983-8

442.

Lv, J., Xie, M. Q., Zhao, S. F., Qiu, W. S., Wang, S. S., & Cao, M. M. (2021). Synergetic fabrication of hybrid drug formulation using biodegradable tri-block copolymeric liquid nanoparticle delivery for gastric cancer chemotherapy. Journal of Molecular Liquids, 340. https://doi.org/10.1016/j.molliq.2021.117066.

443.

Xiong, K., Zhang, Y., Wen, Q., Luo, J., Lu, Y., Wu, Z. X., et al. (2020). Co-delivery of paclitaxel and curcumin by biodegradable polymeric nanoparticles for breast cancer chemotherapy.International Journal of Pharmaceutics, 589. https://doi.org/10.1016/j.ijpharm.2020.119875

444.

Cui, X. J., Sun, Y., Shen, M., Song, K. Q., Yin, X., Di, W., et al. (2018). Enhanced chemotherapeutic efficacy of paclitaxel nanoparticles co-delivered with microRNA-7 by Inhibiting paclitaxel-induced EGFR/ERK pathway activation for ovarian cancer therapy. ACS Applied Materials & Interfaces, 10(9), 7821–7831. https://doi.org/10.1021/acsami.7b19183CrossRef

445.

Ji, Z., Xu, J., Li, M., Wang, H., Xu, B., Yang, Y., et al. (2022). The mechanisms of immune-chemotherapy with nanocomplex codelivery of pTRP-2 and adjuvant of paclitaxel against melanoma. Drug Development and Industrial Pharmacy, 1–19. https://doi.org/10.1080/03639045.2022.2045306

446.

Wiwatchaitawee, K., Mekkawy, A. I., Quarterman, J. C., Naguib, Y. W., Ebeid, K., Geary, S. M., et al. The MEK 1/2 inhibitor PD98059 exhibits synergistic anti-endometrial cancer activity with paclitaxel in vitro and enhanced tissue distribution in vivo when formulated into PAMAM-coated PLGA-PEG nanoparticles. Drug Delivery and Translational Research. https://doi.org/10.1007/s13346-021-01065-7

447.

Zhou, Z. H., Liang, S. Y., Zhao, T. C., Chen, X. Z., Cao, X. K., Qi, M., et al. (2021). Overcoming chemotherapy resistance using pH-sensitive hollow MnO2 nanoshells that target the hypoxic tumor microenvironment of metastasized oral squamous cell carcinoma. Journal of Nanobiotechnology, 19(1). https://doi.org/10.1186/s12951-021-00901-9

448.

Singh, M., Bhatnagar, P., Srivastava, A. K., Kumar, P., Shukla, Y., & Gupta, K. C. (2011). Enhancement of cancer chemosensitization potential of cisplatin by tea polyphenols poly(lactide-co-glycolide) nanoparticles. Journal of Biomedical Nanotechnology, 7(1), 202–202. https://doi.org/10.1166/jbn.2011.1268CrossRefPubMed

449.

Ding, F., Zhang, L. P., Chen, H., Song, H. Q., Chen, S. G., & Xiao, H. H. (2020). Enhancing the chemotherapeutic efficacy of platinum prodrug nanoparticles and inhibiting cancer metastasis by targeting iron homeostasis. Nanoscale Horizons, 5(6), 999–1015. https://doi.org/10.1039/d0nh00148aCrossRefPubMed

450.

Sun, Y., Yang, J. Y., Yang, T., Li, Y. F., Zhu, R. Y., Hou, Y. H., et al. (2021). Co-delivery of IL-12 cytokine gene and cisplatin prodrug by a polymetformin-conjugated nanosystem for lung cancer chemo-gene treatment through chemotherapy sensitization and tumor microenvironment modulation. Acta Biomaterialia, 128, 447–461. https://doi.org/10.1016/j.actbio.2021.04.034CrossRefPubMed

451.

Moghaddam, S. V., Abedi, F., Alizadeh, E., Baradaran, B., Annabi, N., Akbarzadeh, A., et al. (2020). Lysine-embedded cellulose-based nanosystem for efficient dual-delivery of chemotherapeutics in combination cancer therapy. Carbohydrate Polymers, 250. https://doi.org/10.1016/j.carbpol.2020.116861

452.

Lai, K. C., Chueh, F. S., Hsiao, Y. T., Cheng, Z. Y., Lien, J. C., Liu, K. C., et al. (2019). Gefitinib and curcumin-loaded nanoparticles enhance cell apoptosis in human oral cancer SAS cells in vitro and inhibit SAS cell xenografted tumor in vivo. Toxicology and Applied Pharmacology, 382. https://doi.org/10.1016/j.taap.2019.114734

453.

Lotfi-Attari, J., Pilehvar-Soltanahmadi, Y., Dadashpour, M., Alipour, S., Farajzadeh, R., Javidfar, S., et al. (2017). Co-delivery of curcumin and chrysin by polymeric nanoparticles inhibit synergistically growth and hTERT gene expression in human colorectal cancer cells. Nutrition and Cancer-an International Journal, 69(8), 1290–1299. https://doi.org/10.1080/01635581.2017.1367932CrossRef

454.

Javan, N., Ansari, M. H. K., Dadashpour, M., Khojastehfard, M., Bastami, M., Rahmati-Yamchi, M., et al. (2019). Synergistic antiproliferative effects of Co-nanoencapsulated curcumin and chrysin on MDA-MB-231 breast cancer cells through upregulating miR-132 and miR-502c. Nutrition and Cancer-an International Journal, 71(7), 1201–1213. https://doi.org/10.1080/01635581.2019.1599968CrossRef

455.

Hu, B., Sun, D., Sun, C., Sun, Y. F., Sun, H. X., Zhu, Q. F., et al. (2015). A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma. Biochemical and Biophysical Research Communications, 468(4), 525–532. https://doi.org/10.1016/j.bbrc.2015.10.031CrossRefPubMed

456.

Banerjee, S., Sahoo, A. K., Chattopadhyay, A., & Ghosh, S. S. (2014). Recombinant I kappa B alpha-loaded curcumin nanoparticles for improved cancer therapeutics. Nanotechnology, 25(34). https://doi.org/10.1088/0957-4484/25/34/345102

457.

Thao, D. T., Nga, N. T., Van, N. A., & Hung, K. D. (2019). Potential anticancer activities of a combination of curcumin, ginger oleoresin, and rutin solid lipid nanoparticles (Vietlife-Antican) in LLC tumor-bearing mice. Natural Product Communications, 14(6). https://doi.org/10.1177/1934578x19858461

458.

Srivastava, S., Mohammad, S., Gupta, S., Mahdi, A. A., Dixit, R. K., Singh, V., et al. (2018). Chemoprotective effect of nanocurcumin on 5-fluorouracil-induced-toxicity toward oral cancer treatment. National Journal of Maxillofacial Surgery, 9(2), 160. https://doi.org/10.4103/njms.NJMS_27_18CrossRefPubMedPubMedCentral

459.

Qu, W. H., Yang, Q. J., Wang, G. C., Wang, Z. H., Huang, P., Huang, W., et al. (2020). Amphiphilic irinotecan-melampomagnolide B conjugate nanoparticles for cancer chemotherapy. Rsc Advances, 10(15), 8958–8966. https://doi.org/10.1039/d0ra00912aCrossRefPubMedPubMedCentral

460.

Elgohary, M. M., Helmy, M. W., Mortada, S. M., & Elzoghby, A. O. (2018). Dual-targeted nano-in-nano albumin carriers enhance the efficacy of combined chemo/herbal therapy of lung cancer. Nanomedicine, 13(17), 2221–2244. https://doi.org/10.2217/nnm-2018-0097CrossRefPubMed

461.

Kamel, N. M., Helmy, M. W., Samaha, M. W., Ragab, D., & Elzoghby, A. O. (2019). Multicompartmental lipid-protein nanohybrids for combined tretinoin/herbal lung cancer therapy. Nanomedicine, 14(18), 2461-+. https://doi.org/10.2217/nnm-2019-0090CrossRefPubMed

462.

Singh, R. P., Sharma, G., Sonali, Singh, S., Kumar, M., Pandey, B. L., et al. (2016). Vitamin E TPGS conjugated carbon nanotubes improved efficacy of docetaxel with safety for lung cancer treatment. Colloids and Surfaces B-Biointerfaces, 141, 429–442. https://doi.org/10.1016/j.colsurfb.2016.02.011CrossRefPubMed

463.

Wu, Y. L., Liu, J. P., Movahedi, F., Gu, W. Y., Xu, T. F., & Xu, Z. P. (2020). Enhanced prevention of breast tumor metastasis by nanoparticle-delivered vitamin e in combination with interferon-gamma. Advanced Healthcare Materials, 9(6). https://doi.org/10.1002/adhm.201901706

464.

El-Lakany, S. A., Elgindy, N. A., Helmy, M. W., Abu-Serie, M. M., & Elzoghby, A. O. (2018). Lactoferrin-decorated vs PEGylated zein nanospheres for combined aromatase inhibitor and herbal therapy of breast cancer. Expert Opinion on Drug Delivery, 15(9), 835–850. https://doi.org/10.1080/17425247.2018.1505858CrossRefPubMed

465.

Maroufi, N. F., Vahedian, V., Mazrakhondi, S. A. M., Kooti, W., Khiavy, H. A., Bazzaz, R., et al. (2020). Sensitization of MDA-MBA231 breast cancer cell to docetaxel by myricetin loaded into biocompatible lipid nanoparticles via sub-G1 cell cycle arrest mechanism. Naunyn-Schmiedebergs Archives of Pharmacology, 393(1), 1–11. https://doi.org/10.1007/s00210-019-01692-5CrossRefPubMed

466.

Deepika, M. S., Thangam, R., Sheena, T. S., Vimala, R. T. V., Sivasubramanian, S., Jeganathan, K., et al. (2019). Dual drug loaded PLGA nanospheres for synergistic efficacy in breast cancer therapy. Materials Science & Engineering C-Materials for Biological Applications, 103. https://doi.org/10.1016/j.msec.2019.05.001

467.

Snima, K. S., Nair, R. S., Nair, S. V., Kamath, C. R., & Lakshmanan, V. K. (2015). Combination of anti-diabetic drug metformin and boswellic acid nanoparticles: A novel strategy for pancreatic cancer therapy. Journal of Biomedical Nanotechnology, 11(1), 93–104. https://doi.org/10.1166/jbn.2015.1877CrossRefPubMed

468.

Mogheri, F., Jokar, E., Afshin, R., Akbari, A. A., Dadashpour, M., Firouzi-amandi, A., et al. (2021). Co-delivery of metformin and silibinin in dual-drug loaded nanoparticles synergistically improves chemotherapy in human non-small cell lung cancer A549 cells. Journal of Drug Delivery Science and Technology, 66. https://doi.org/10.1016/j.jddst.2021.102752

469.

Mahira, S., Kommineni, N., Husain, G. M., & Khan, W. (2019). Cabazitaxel and silibinin co-encapsulated cationic liposomes for CD44 targeted delivery: A new insight into nanomedicine based combinational chemotherapy for prostate cancer. Biomedicine & Pharmacotherapy, 110, 803–817. https://doi.org/10.1016/j.biopha.2018.11.145CrossRef

470.

Sun, X. P., Veeraraghavan, V. P., Surapaneni, K. M., Hussain, S., Mathanmohun, M., Alharbi, S. A., et al. (2021). Eugenol-piperine loaded polyhydroxy butyrate/polyethylene glycol nanocomposite-induced apoptosis and cell death in nasopharyngeal cancer (C666–1) cells through the inhibition of the PI3K/AKT/mTOR signaling pathway. Journal of Biochemical and Molecular Toxicology, 35(4). https://doi.org/10.1002/jbt.22700

471.

Garg, N. K., Tyagi, R. K., Sharma, G., Jain, A., Singh, B., Jain, S., et al. (2017). Functionalized lipid-polymer hybrid nanoparticles mediated codelivery of methotrexate and aceclofenac: A synergistic effect in breast cancer with improved pharmacokinetics attributes. Molecular Pharmaceutics, 14(6), 1883–1897. https://doi.org/10.1021/acs.molpharmaceut.6b01148CrossRefPubMed

472.

Hu, N., Yin, J. F., Ji, Z., Hong, Y. D., Wu, P. Y., Bian, B. X., et al. (2017). Strengthening gastric cancer therapy by trastuzumab-conjugated nanoparticles with simultaneous encapsulation of anti-MiR-21 and 5-fluorouridine. Cellular Physiology and Biochemistry, 44(6), 2158–2173. https://doi.org/10.1159/000485955CrossRefPubMed

473.

Li, C., Hu, J. Q., Li, W. Y., Song, G. S., & Shen, J. (2017). Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment. Biomaterials Science, 5(1), 77–88. https://doi.org/10.1039/c6bm00449kCrossRef

474.

Ding, S., Xiong, J., Lei, D., Zhu, X. L., & Zhang, H. J. (2018). Recombinant nanocomposites by the clinical drugs of Abraxane (R) and Herceptin (R) as sequentially dual-targeting therapeutics for breast cancer. Journal of Cancer, 9(3), 502–511. https://doi.org/10.7150/jca.22163CrossRefPubMedPubMedCentral

475.

El-Leithy, E. S., Hassan, S. A., & Abdel-Rashid, R. S. (2019). Tamoxifen citrate/coenzyme Q10 as smart nanocarriers bitherapy for breast cancer: Cytotoxicity, genotoxicity, and antioxidant activity. Journal of Drug Delivery Science and Technology, 51, 36–44. https://doi.org/10.1016/j.jddst.2019.02.010CrossRef

476.

Chang, Y., Wu, F., Pandey, N. K., Chudal, L., Xing, M. Y., Zhang, X. L., et al. (2020). Combination of disulfiram and copper-cysteamine nanoparticles for an enhanced antitumor effect on esophageal cancer. Acs Applied Bio Materials, 3(10), 7147–7157. https://doi.org/10.1021/acsabm.0c00949CrossRefPubMedPubMedCentral

477.

Huang, P., Wang, G. C., Wang, Z. H., Zhang, C. C., Wang, F. M., Cui, X. X., et al. (2020). Floxuridine-chlorambucil conjugate nanodrugs for ovarian cancer combination chemotherapy. Colloids and Surfaces B-Biointerfaces, 194. https://doi.org/10.1016/j.colsurfb.2020.111164.

478.

Kumbham, S., Paul, M., Itoo, A., Ghosh, B., & Biswas, S. (2022). Oleanolic acid-conjugated human serum albumin nanoparticles encapsulating doxorubicin as synergistic combination chemotherapy in oropharyngeal carcinoma and melanoma. International Journal of Pharmaceutics, 614, 121479. https://doi.org/10.1016/j.ijpharm.2022.121479CrossRefPubMed

479.

Wang, X., Liu, Y., Wang, S. J., Shi, D. H., Zhou, X. G., Wang, C. Y., et al. (2015). CD44-engineered mesoporous silica nanoparticles for overcoming multidrug resistance in breast cancer. Applied Surface Science, 332, 308–317. https://doi.org/10.1016/j.apsusc.2015.01.204CrossRef

480.

Zhang, S. P., Guo, N., Wan, G. Y., Zhang, T., Li, C. Y., Wang, Y. F., et al. (2019). pH and redox dual-responsive nanoparticles based on disulfide-containing poly(beta-amino ester) for combining chemotherapy and COX-2 inhibitor to overcome drug resistance in breast cancer. Journal of Nanobiotechnology, 17(1). https://doi.org/10.1186/s12951-019-0540-9

481.

Helmy, S. A., El-Mofty, S., El Gayar, A. M., El-Sherbiny, I. M., & El-Far, Y. M. (2022). Novel doxorubicin/folate-targeted trans-ferulic acid-loaded PLGA nanoparticles combination: In-vivo superiority over standard chemotherapeutic regimen for breast cancer treatment. Biomedicine & Pharmacotherapy, 145. https://doi.org/10.1016/j.biopha.2021.112376

482.

Huang, I. P., Sun, S. P., Cheng, S. H., Lee, C. H., Wu, C. Y., Yang, C. S., et al. (2011). Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein-mediated drug resistance. Molecular Cancer Therapeutics, 10(5), 761–769. https://doi.org/10.1158/1535-7163.Mct-10-0884CrossRefPubMed

483.

Mi, F. L., Wang, L. F., Chu, P. Y., Peng, S. L., Feng, C. L., Lai, Y. J., et al. (2018). Active tumor-targeted co-delivery of epigallocatechin gallate and doxorubicin in nanoparticles for combination gastric cancer therapy. Acs Biomaterials Science & Engineering, 4(8), 2847–2859. https://doi.org/10.1021/acsbiomaterials.8b00242CrossRef

484.

Wan, G. Y., Liu, Y., Shi, S. R., Chen, B. W., Wang, Y., Wang, H. M., et al. (2016). Hematoporphyrin and doxorubicin co-loaded nanomicelles for the reversal of drug resistance in human breast cancer cells by combining sonodynamic therapy and chemotherapy. Rsc Advances, 6(102), 100361–100372. https://doi.org/10.1039/c6ra22724dCrossRef

485.

Dong, X. L., Sun, Y., Li, Y. Y., Ma, X. Y., Zhang, S. Q., Yuan, Y., et al. (2021). Synergistic combination of bioactive hydroxyapatite nanoparticles and the chemotherapeutic doxorubicin to overcome tumor multidrug resistance. Small, 17(18). https://doi.org/10.1002/smll.202007672

486.

Khdair, A., Chen, D., Patil, Y., Ma, L. N., Dou, Q. P., Shekhar, M. P. V., et al. (2010). Nano particle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance. Journal of Controlled Release, 141(2), 137–144. https://doi.org/10.1016/j.jconrel.2009.09.004CrossRefPubMed

487.

Fu, J. K., Li, T., Yang, Y. Z., Jiang, L. P., Wang, W. H., Fu, L. J., et al. (2021). Activatable nanomedicine for overcoming hypoxia-induced resistance to chemotherapy and inhibiting tumor growth by inducing collaborative apoptosis and ferroptosis in solid tumors. Biomaterials, 268. https://doi.org/10.1016/j.biomaterials.2020.120537

488.

Li, S. Y., Sun, R., Wang, H. X., Shen, S., Liu, Y., Du, X. J., et al. (2015). Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells. Journal of Controlled Release, 205, 7–14. https://doi.org/10.1016/j.jconrel.2014.11.011CrossRefPubMed

489.

Wang, Y., Saad, M., Pakunlu, R. I., Khandare, J. J., Garbuzenko, O. B., Garbuzenko, O. B., et al. (2008). Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 alpha enhances the efficacy of chemotherapy in drug-resistant tumor. Clinical Cancer Research, 14(11), 3607–3616. https://doi.org/10.1158/1078-0432.Ccr-07-2020CrossRefPubMed

490.

Lv, X. M., Guo, Q. S., & Xu, L. M. (2020). Study on the chemotherapeutic effect and mechanism of doxorubicin hydrochloride on drug-resistant gastric cancer cell lines using metal-organic framework fluorescent nanoparticles as carriers. Journal of Nanomaterials, 2020. https://doi.org/10.1155/2020/6681749

491.

Kumar, B. N. P., Puvvada, N., Rajput, S., Sarkar, S., Mahto, M. K., Yallapu, M. M., et al. (2018). Targeting of EGFR, VEGFR2, and Akt by engineered dual drug encapsulated mesoporous silica-gold nanoclusters sensitizes tamoxifen-resistant breast cancer. Molecular Pharmaceutics, 15(7), 2698–2713. https://doi.org/10.1021/acs.molpharmaceut.8b00218CrossRefPubMed

492.

Wang, C., Liu, B., Xu, X. L., Zhuang, B., Li, H. X., Yin, J. Q., et al. (2016). Toward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolide nanomedicine. Oncotarget, 7(7), 8360–8372. https://doi.org/10.18632/oncotarget.7073CrossRefPubMedPubMedCentral

493.

Ganthala, P. D., Alavala, S., Chella, N., Andugulapati, S. B., Bathini, N. B., & Sistla, R. (2022). Co-encapsulated nanoparticles of Erlotinib and Quercetin for targeting lung cancer through nuclear EGFR and PI3K/AKT inhibition. Colloids and Surfaces B-Biointerfaces, 211. https://doi.org/10.1016/j.colsurfb.2021.112305.

494.

Zhang, L. L., Zhu, H. Y., Gu, Y., Wang, X. H., & Wu, P. P. (2019). Dual drug-loaded PLA nanoparticles bypassing drug resistance for improved leukemia therapy. Journal of Nanoparticle Research, 21(4). https://doi.org/10.1007/s11051-018-4430-0

495.

He, L. Z., Lai, H. Q., & Chen, T. F. (2015). Dual-function nanosystem for synergetic cancer chemo-/radiotherapy through ROS-mediated signaling pathways. Biomaterials, 51, 30–42. https://doi.org/10.1016/j.biomaterials.2015.01.063CrossRefPubMed

496.

Huang, Y. Y., Luo, Y., Zheng, W. J., & Chen, T. F. (2014). Rational design of cancer-targeted BSA protein nanoparticles as radiosensitizer to overcome cancer radioresistance. ACS Applied Materials & Interfaces, 6(21), 19217–19228. https://doi.org/10.1021/am505246wCrossRef

497.

Lang, L. W., Lam, T., Chen, A., Jensen, C., Duncan, L., Kong, F. C., et al. (2020). Circumventing AKT-associated radioresistance in oral cancer by novel nanoparticle-encapsulated capivasertib. Cells, 9(3). https://doi.org/10.3390/cells9030533

498.

Wang, N., Feng, Y. X., Zeng, L. L., Zhao, Z. N., & Chen, T. F. (2015). Functionalized multiwalled carbon nanotubes as carriers of ruthenium complexes to antagonize cancer multidrug resistance and radioresistance. ACS Applied Materials & Interfaces, 7(27), 14933–14945. https://doi.org/10.1021/acsami.5b03739CrossRef

499.

Rajamani, S., Radhakrishnan, A., Sengodan, T., & Thangavelu, S. (2018). Augmented anticancer activity of naringenin-loaded TPGS polymeric nanosuspension for drug resistive MCF-7 human breast cancer cells. Drug Development and Industrial Pharmacy, 44(11), 1752–1761. https://doi.org/10.1080/03639045.2018.1496445CrossRefPubMed

500.

Guo, Y., Liu, S., Luo, F., Tang, D., Yang, T., Yang, X., et al. (2022). A nanosized codelivery system based on intracellular stimuli-triggered dual-drug release for multilevel chemotherapy amplification in drug-resistant breast cancer. Pharmaceutics, 14(2). https://doi.org/10.3390/pharmaceutics14020422

501.

Zhang, J., Liang, L. J., Li, Z. Y., Shen, Y. T., Guan, X., Yue, J., et al. (2020). Multi-functionalized Nano-conjugate for combating multidrug resistant breast cancer via starvation-assisted chemotherapy.Materials Science & Engineering C-Materials for Biological Applications, 116. https://doi.org/10.1016/j.msec.2020.111127

502.

Kojima, K., Takahashi, S., Saito, S., Endo, Y., Nittami, T., Nozaki, T., et al. (2018). Combined effects of Fe3O4 nanoparticles and chemotherapeutic agents on prostate cancer cells in vitro. Applied Sciences-Basel, 8(1). https://doi.org/10.3390/app8010134

503.

Wang, Q., Zhang, X. Y., Sun, Y., Wang, L. T., Ding, L., Zhu, W. H., et al. (2019). Gold-caged copolymer nanoparticles as multimodal synergistic photodynamic/photothermal/chemotherapy platform against lethality androgen-resistant prostate cancer. Biomaterials, 212, 73–86. https://doi.org/10.1016/j.biomaterials.2019.05.009CrossRefPubMed

504.

Chang, P. Y., Peng, S. F., Lee, C. Y., Lu, C. C., Tsai, S. C., Shieh, T. M., et al. (2013). Curcumin-loaded nanoparticles induce apoptotic cell death through regulation of the function of MDR1 and reactive oxygen species in cisplatin-resistant CAR human oral cancer cells. International Journal of Oncology, 43(4), 1141–1150. https://doi.org/10.3892/ijo.2013.2050CrossRefPubMed

505.

Kotmakci, M., Cetintas, V. B., & Kantarci, A. G. (2017). Preparation and characterization of lipid nanoparticle/pDNA complexes for STAT3 downregulation and overcoming chemotherapy resistance in lung cancer cells. International Journal of Pharmaceutics, 525(1), 101–111. https://doi.org/10.1016/j.ijpharm.2017.04.034CrossRefPubMed

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Current advances in nanoformulations of therapeutic agents targeting tumor microenvironment to overcome drug resistance

Abstract

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2023

Potential biomarkers for immunotherapy in NSCLC

Next-generation immune checkpoint inhibitors as promising functional molecules in cancer therapeutics

Tetrahydrocannabinols: potential cannabimimetic agents for cancer therapy

New progress of tuberculosis scar carcinoma

Nanoparticle-mediated cancer cell therapy: basic science to clinical applications

Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer